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Abstract
Mechanisms by which Metaflammation and Adiponectin Regulates Glucose and Lipid
Metabolism
Xiruo Li
2021

Obesity and Type 2 Diabetes mellitus (T2DM) are among the most serious global
health problems as they are increasing in prevalence and related to many chronic
diseases, including cardiovascular and cerebrovascular diseases, cancer and other
metabolic disorders. Obesity increases the risk for T2DM through the development of lowgrade inflammation and insulin resistance. Specifically, studies have shown that enhanced
inflammation in adipose tissue is an essential player in the progression of insulin
resistance and T2DM in obese individuals. However, how immune cells sense nutritional
status and contribute to whole-body metabolism are largely unknown. In addition, most of
the currently available therapies do not address the root cause of T2DM: insulin resistance.
Pharmacological agents that improve diabetes have limited success due to side effects
and decline in efficacy as most patients develop resistance over time.

As such,

understanding the pathogenesis of T2DM and finding new interventions to ameliorate
insulin resistance are of great interest.
In this doctoral dissertation, I describe work that elucidates the nutritional
regulation of macrophage function and its contribution to whole-body metabolism, as well
as the mechanisms by which a new potential treatment, adiponectin, ameliorates insulin
resistance. Protein O-GlcNAcylation is thought to be a metabolic sensor that modulates
cell signaling. I showed that overnutrition stimulated nutrient-sensing O-linked β-Nacetylglucosamine (O-GlcNAc) signaling in macrophages and O-GlcNAc signaling was
down-regulated during macrophage pro-inflammatory polarization. Further, mice with O-

GlcNAc transferase (Ogt) deletion in macrophages and other myeloid cells displayed
enhanced macrophage pro-inflammatory activation in adipose tissue and lipolysis,
increased ectopic lipid accumulation in peripheral tissues, and exacerbated tissue-specific
and whole-body insulin resistance in diet-induced obese mice. O-GlcNAc signaling
inhibited macrophage pro-inflammatory polarization by catalyzing ribosomal protein S6
kinase beta-1 (S6K1) serine 489 O-GlcNAcylation and suppressing S6K1 phosphorylation.
These studies uncovered O-GlcNAc signaling as a novel homeostatic regulator at the
interface of inflammation and metabolism and suggested that O-GlcNAc signaling may
serve as a therapeutic target for obesity, diabetes, and other immune-related diseases.
Finally, I examined the mechanisms for the anti-diabetic effect of adiponectin.
Adiponectin has emerged as a promising insulin-sensitizing adipokine and a potential
therapy to treat T2DM; however, the mechanisms by which adiponectin administration
improves insulin sensitivity were unclear. To address this question, I examined the effects
of a 2-week continuous subcutaneous infusion of globular adiponectin (gAcrp30) or saline
on glucose and lipid metabolism in a high-fat diet (HFD) fed mouse model. Whole-body
and tissue-specific insulin action was assessed by a hyperinsulinemic-euglycemic clamp
(HEC). gAcrp30-treated mice displayed reduced fasting plasma glucose and insulin
concentrations and increased glucose infusion rate during the HEC, reflecting increased
whole-body insulin sensitivity. Increased insulin sensitivity could be attributed to reduced
endogenous glucose production and increased glucose uptake in muscle and adipose
tissues. We found that these liver and muscle sensitivity improvements were associated
with reductions in the plasma membrane-associated diacylglycerol (DAG) content, and
contrary to prior studies, were independent of reductions in total ceramide content. These
effects in turn led to decreased protein kinase Cε (PKCε) activation in liver, decreased
PKCε/PKCθ activity in muscle, and improved insulin signaling in these tissues. I further
demonstrated that globular adiponectin (gAcrp30) and full-length adiponectin (Acrp30)

reverse insulin resistance in HFD-fed mice through reductions in ectopic lipid in liver and
muscle likely by stimulation of lipoprotein lipase (LPL) activity in white adipose tissue and
increased epithelial nitric oxide synthase (eNOS)/ 5' AMP-activated protein kinase (AMPK)
activation and fat oxidation in muscle.
Taken together, the work presented in the dissertation provides novel mechanistic
insight into the regulation and function of O-GlcNAc signaling in the immunometabolism
and the mechanisms by which adiponectin reverses HFD-induced liver and muscle insulin
resistance in mice. As such, adiponectin and O-GlcNAc signaling activators, such as
glutamine and glucosamine, could serve as viable treatment options for T2DM, insulin
resistance and other obesity-associated morbidities.
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CHAPTER 1
Introduction to Obesity and Insulin Resistance
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Obesity and Type 2 Diabetes mellitus (T2DM) are two of the major healthcare
burdens of the 21st century, with an incidence that increases yearly (1). Obesity has almost
tripled globally since the 1970s (2). More than 1.9 billion adults (40% of the world adult
population) were overweight and more than 650 million were categorized as obese (3).
T2DM currently affects more than 30.3 million people in the United States and the
prevalence of diabetes is growing rapidly, mirroring an increase in the prevalence of
obesity and overweight people (Fig. 1). As the incidence and prevalence of diabetes
continue to rise, the Centers for Disease Control and Prevention estimate one in three
Americans will suffer from T2DM by 2050 (4). Obesity serves as an important risk factor
for the development of numerous diseases, including T2DM, non-alcoholic fatty liver
disease (NAFLD), cardiovascular diseases (CVD), more than one dozen cancers and
some immune-related disorders. Insulin resistance plays a critical role in the pathogenesis
of T2DM and other obesity-related diseases, such as NAFLD and CVD (5-7). As such,
understanding the pathogenesis of insulin resistance and finding effective therapies have
become essential to treat T2DM and obesity-related diseases.
Chronic obesity-associated inflammation, particularly in adipose tissue and liver,
has been widely reported as a significant pathogenic factor associated with insulin
resistance and T2D in both rodents and humans (8-10). In obese subjects, adipose tissue
is enriched with pro-inflammatory immune cells such as macrophages and lymphocytes
(8). These immune cells secrete excessive cytokines such as IL-6 and TNFα which have
been shown to have lipolytic effects and increase ectopic lipid accumulation in insulinresponsive tissues (9, 11, 12). The relationship between chronic low-grade obesityassociated inflammation (metaflammation) and insulin resistance will be explored in
Chapter 2.
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Figure 1. Number of people with diabetes worldwide and per region in 2017 and
2045 (20–79 years) (http://diabetesatlas.org/).
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The association between ectopic lipids and insulin resistance is widely accepted
(13-15). Although studies in normal weight, non-diabetic adults found that triglyceride
(TAG) content was a stronger predictor of insulin resistance than circulating fatty acid in
soleus muscle (16), experiments showed that TG concentrations are dissociated from
insulin resistance (7, 16). One hypothesis proposed that its precursor, DAG may induce
insulin resistance. Increased DAG level impairs insulin action via activation and membrane
translocation of protein kinase Cε (PKCε) in liver(17, 18) and both PKCε and PKCθ in
skeletal muscle, which will impair subsequent insulin receptor kinase (IRK) activity (14, 19,
20). Hepatic insulin resistance will lead to reduced suppression of gluconeogenesis and
insulin resistance in muscle will result in reduced glucose uptake. In addition to liver and
muscle, insulin resistance develops in white adipose tissue (WAT). In this condition, insulin
fails to suppress WAT lipolysis, which will lead to increased free fatty acid delivery into
liver and muscle to further raise TAG and DAG levels (6, 7). In addition to the direct effect
of insulin, experiments from our laboratory have shown that fasting hyperglycemia in
rodent models of T2D is caused by inappropriate increases in hepatic gluconeogenesis in
the setting of increased white adipose tissue (WAT) lipolysis and increased glycerol and
acetyl CoA delivery to the liver (9). Increased conversion of glycerol to glucose is driven
by a substrate push mechanism and conversion of pyruvate to glucose is increased
through allosteric activation of pyruvate carboxylase (PC) by acetyl CoA. Published papers
regarding the insulin signaling and lipid-induced insulin resistance will be reviewed in
Chapter 3.
Mitigating insulin resistance and achieving normoglycemia is a critical objective in
the treatment of T2DM, which would reduce the risk of diabetes-associated complications
(21, 22). Adiponectin has emerged as an anti-diabetic, anti-inflammatory and antiatherogenic adipokine(23, 24). Adiponectin is an adipokine mostly secreted by adipose
tissue. Studies in humans and monkeys showed that plasma adiponectin levels correlate
8

significantly with whole-body insulin sensitivity (25, 26). Overexpression or administration
of adiponectin results in a decrease in hyperglycemia and improvement in systemic insulin
sensitivity (23, 27), whereas adiponectin-deficient mice exhibit impaired insulin sensitivity
and diabetes (24, 28). As such, adiponectin may serve as a viable treatment option for
T2DM, insulin resistance and other obesity-related diseases. The current available
therapies to treat T2DM and the proposed mechanisms of adiponectin’s anti-diabetic
effect will be discussed in Chapter 4.
With the context provided above, the remainder of the dissertation will describe the
original research I conducted during my PhD that fulfilled the doctoral requirements of the
Yale University Graduate School of Arts and Sciences. The research project to study how
immune cells, especially macrophages in adipose tissues, sense nutritional clues and
contribute to the whole-body metabolism will be described in Chapter 5. In this project, I
used a novel O-GlcNAc transferaseflox (Ogtflox) LyzM-Cre+/- (OGT MKO) mouse model by
crossing Ogtflox mice (provided by Dr. Steven Jones) with LyzM-Cre mice. Dr. Steven
Jones’ group found that although OGT deletion in cardiomyocyte did not cause any
significant functional change in sham-operated mice, infarcted cardiomyocyte OGT KO
mice and long-term OGT loss in cardiomyocyte significantly exacerbated cardiac
dysfunction compared with WT (29, 30). This project reveals an intrinsic mechanism
maintaining adipose tissue and whole-body metabolic homeostasis during overnutrition
through macrophage O-GlcNAc signaling. Chapter 6 will describe a novel mechanism by
which adiponectin reverses insulin resistance in high-fat diet fed mice, providing important
therapeutic implications for treating insulin resistance and T2DM. Finally, Chapter 7 will
summarize the whole dissertation research in a broader context and point out potential
directions for future studies.
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CHAPTER 2
Chronic Low-grade Inflammation in Adipose Tissues Links Obesity to
Insulin Resistance and Type 2 Diabetes

10

In obesity, the chronic low-grade metabolic inflammation (metaflammation)
develops in multiple organs such as adipose (31, 32), liver (33, 34), skeletal muscle (35,
36), pancreas (37, 38), brain (39, 40) and gut (41, 42) and is defined by increased
infiltration and activation of innate and adaptive immune cells. Adipose tissue inflammation,
the major and most well-characterized form of metaflammation, negatively impacts wholebody energy homeostasis and has been linked to the development of obesity-induced
insulin resistance (32, 43, 44). In obesity, adipose tissue is enriched with pro-inflammatory
immune cells such as macrophages (31), neutrophils (45), T cells (46) and B cells (47).
These immune cells secrete excessive cytokines such as IL-6 and TNFα which have been
shown to have lipolytic effects both in vitro and in vivo (11, 12, 48).
Macrophages, which are the primary immunue cells studied in the dissertation, are
the most abundant innate immune cells infiltrating and accumulating into adipose tissues
and constitute up to 40% of all adipose tissue cells (8, 49). It is suggested that
macrophages are the primary sources of pro-inflammatory cytokines such as IL-6 and
TNF-α (7). In obesity, adipose tissue macrophages are polarized into pro-inflammatory
macrophages and secrete excessive pro-inflammatory cytokines, leading to increased
adipose tissues lipolysis (Fig. 2). Increased lipolysis leads to increased free fatty acid
delivery into liver and skeletal muscle to raise TAG and diacylglycerol DAG levels. In
addition, increased lipolysis has also been shown to drive increased rate of hepatic
gluconeogenesis by increasing acetyl CoA levels as well as glycerol influx, causing fasting
hyperglycemia (50).
Besides macrophages, many other immune cells (e.g., neutrophils, dendritic cells,
mast cells, B cells, and T cells) reside in adipose tissue during obesity, playing a vital role
in the development of adipose tissue inflammation and insulin resistance. Neutrophils are
relatively rare in adipose tissue of lean mice (51), but they are the first immune cells
recruited to adipose tissues after 3 days of HFD and prolonged for over 90 days (45, 52).
11

Neutrophils mediate insulin resistance in mice by producing TNF-α, MCP-1 and elastase,
which impairs glucose uptake in adipose tissue and degrades IRS-1 (45, 53, 54). Dendritic
cells accumulate in adipose tissue of HFD-fed mice and obese humans (55). Dendritic
cells have been shown to induce insulin resistance by recruiting macrophages in adipose
tissue and increasing pro-inflammatory cytokine IL-6 production (56, 57). Similarly, mast
cells infiltrate into adipose tissue and significantly increase in the adipose tissue of mice
and humans with obesity and T2DM (58, 59). Mast cells are regulated by IL-6 and IFN-γ
but not by TNF-α and they promote inflammation in adipose tissue by mediating
macrophage infiltration (58, 60). B cells and T cells also play essential roles in macrophage
infiltration and activation (8). B cells in adipose tissue are quite unique and different from
B cells found in other tissues (61). B cells significantly increase in the adipose tissue of
obese mice and induce insulin resistance by producing chemokines and promoting the
recruitment of neutrophils, T cells and macrophages (8, 51). B cells also produce
immunoglobulin G antibodies and pro-inflammatory cytokines, which may also lead to
increased inflammation in adipose tissue (47, 62). CD3+ T cells are the second largest
immune cell population in adipose tissue and are increased in obese mice (8). T cells can
be further divided into CD4+ and CD8+ T cells. CD8+ T cells are increased in the adipose
tissue and promote chemotaxis and macrophage activation in obesity (46). The
abundance of pro-inflammatory CD3+CD4+ T helper (Th1) cells is increased in obesity,
while the number of anti-inflammatory CD3+CD4+Th2 cells and CD3+CD4+FOXP3+ (Treg)
cells is reduced, which contribute to increased inflammation and reduced insulin sensitivity
(8, 63, 64).
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Figure 2. Schematic representations of the metaflammation-lipolysis-insulin
resistance model.
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Chapter 3
Lipid-Induced Insulin Resistance

14

It is well known that insulin resistance and T2DM are closely associated with
obesity and ectopic lipid accumulation (6, 65). In the early stages of obesity, healthy
adipose tissue expansion buffers the excessive calorie intake and limits net energy flow
into lean body components such as liver and skeletal muscle. However, in the chronic
stage of obesity, disrupted energy buffering capacity of adipose tissue causes energy
spillover in the form of accelerated lipolysis, leading to ectopic lipid accumulation and
subsequent metabolic syndromes, such as hepatic steatosis and insulin resistance (65).
DAGs and ceramides have emerged as the two best-studied ectopic lipids that
have been proposed to mediate lipid-induced insulin resistance (66). DAG is an important
intermediate in TAG metabolism and an essential second messenger that can activate
PKC. Numerous studies have demonstrated the association between DAG and insulin
resistance. Previous studies in human liver and muscle biopsies have shown that total
DAG content was more strongly associated with insulin resistance in liver and muscle than
other putative mediators of insulin resistance (67, 68). More evidence suggests that DAG
in liver and muscle was significantly correlated with insulin resistance (suppression of
glucose production, HOMA-IR, insulin signaling cascade and etc.) (19, 69, 70). In subjects
with hepatic insulin resistance, sn-1,2-DAG accumulates in the liver and activates PKCε
(71). Insulin receptor kinase (IRK) Thr1160 has been recently identified as a PKCε
substrate and IRK phosphorylation destabilizes the active configuration of the IRK, leading
to impaired IRK activity and downstream insulin signaling (17). In subjects with muscle
insulin resistance, sn-1,2-DAG activates PKCθ and further increases insulin receptor
substrate (IRS)-1 serine phosphorylation, which inhibits insulin-stimulated IRS-1 tyrosine
phosphorylation and downstream insulin signaling (68, 72-74).
Ceramide is another potential mediator of insulin resistance in liver and muscle
(75-78). Two major mechanisms have been proposed to explain ceramide-induced insulin
resistance (79-81). The first mechanism is that ceramides activate PKCζ, resulting in
15

reduced translocation of protein kinase B (Akt) to the plasma membrane and impaired
downstream insulin action. Another mechanism is that ceramides activate protein kinase
2A, which could further dephosphorylate and inactivate Akt.

16

Chapter 4
Current Treatments for Type 2 Diabetes and an Introduction to Adiponectin
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T2DM is one of the leading causes of mortality in the adult population worldwide
(82, 83) and plays a critical predisposing role in the pathogenesis of metabolic syndrome,
nonalcoholic fatty liver disease (NAFLD) and cardiovascular disease (CVD) (5-7, 84). A
combination of lifestyle changes and pharmacological treatment is important to achieve
great metabolic control in diabetes patients (85). The current available treatments for
T2MD and a potential novel therapy, adiponectin will be briefly reviewed.
Metformin is considered as the first-line treatment for T2DM. In the intestines,
metformin can change the composition of gut microbiota and activates mucosal AMPactivated protein-kinase (AMPK) that maintains the integrity of the intestinal barrier (86,
87). In the liver, metformin can inhibit gluconeogenesis by several mechanisms (88). The
most frequent side effects of metformin are gastrointestinal and metformin reduces
intestinal absorption of vitamin B12 (85). Sulfonylureas and meglitinides can stimulate
insulin release by similar mechanisms (89). Sulfonylureas are a classic first or second-line
therapy for patients with T2DM (90). The main problems related to sulfonylureas and
meglitinides are loss of efficacy due to beta cell dysfunction, hypoglycemia, weight gain
and cardiovascular risk (91-96). The alpha-glucosidase inhibitors delay carbohydrate
absorption and digestion, resulting in a reduction in postprandial hyperglycemia and TAGs
(97, 98). The side effects are mainly gastrointestinal and α-glucosidase inhibitors can
produce asymptomatic elevation of liver enzymes (98, 99).
Thiazolidinediones (TDZs) increase insulin sensitivity, activate peroxisome
proliferator-activated receptors (PPARs) and preserve pancreatic beta cell function (85).
The main side effects of TDZs are weight gain and heart failure (100, 101). Dipeptidyl
peptidase-4 inhibitors (iDPP4) are used as monotherapy in patients inadequately
controlled by diet and exercise, and dual therapy in combination with metformin, TZDs
and insulin. iDPP4 inhibit DPP4, an enzyme that rapidly inactivates incretins (GLP1 and
GIP), and therefore increase incretin concentrations, which can further improve insulin
18

secretion and inhibit glucagon (85). The side effects of iDPP4 are rare. Sodium glucose
co-transporter-2 inhibitors (iSGLT2) inhibit renal reabsorption of glucose, increase its
excretion and reduce hyperglycemia in patients with T2DM, resulting in a reduction in
weight and blood pressure (102). Urogenital tract infections, orthostatic hypotension and
volume depletion are the main side effects of iSGLT2 (103).
Almost all currently available therapies have side effects, and they are often
inadequate. Lots of studies have been shown that current therapies are valuable for
reducing microvascular complications, but are not effective in reducing cardiovascular
events, probably even being harmful in those with advanced type 2 diabetes (104, 105).
So cardiovascular safety of anti-diabetic medications has become another essential
requirement for new medications. In addition, given that current treatment approaches do
not prevent or slow the loss of β-cell function, there is clearly an urgent need for alternative
approaches. As such, these obstacles highlight a clear scientific and health priority for
developing more effective treatments for T2DM and insulin resistance. Adiponectin has
emerged as an anti-diabetic, anti-inflammatory and anti-atherogenic adipokine produced
exclusively by adipocytes as the form of full-length and globular adiponectin (23, 24).
Globular adiponectin is generated by proteolytic cleavage of full-length adiponectin (106).
Adiponectin forms different multimers and is present in serum in trimer, hexamer or high
molecular weight form (106). Almost all adiponectin appears to exist as full-length
adiponectin in plasma, globular adiponectin only accounts for a relatively small amount.
But globular adiponectin is more potent than the full-length adiponectin. Plasma
adiponectin levels in humans range from 0.5 to 30 μg/ml, which is about 1000-fold higher
than the concentrations of most other hormones such as leptin and insulin (107). Plasma
adiponectin levels are decreased in obesity, insulin resistance and T2DM (108, 109).
Administration of adiponectin has been shown to produce a rapid glucose-lowering effect
and ameliorate insulin resistance in mice (110-112). Studies in humans and monkeys
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showed that plasma adiponectin levels correlate significantly with whole-body insulin
sensitivity (25, 26). Overexpression or administration of adiponectin results in a decrease
in hyperglycemia, improvement in systemic insulin sensitivity, protection cardiovascular
health and maintenance of β-cell function (23, 27, 113, 114), whereas adiponectindeficient mice exhibit impaired insulin sensitivity and diabetes (24, 28).
The effect of adiponectin seems to be mediated by several mechanisms (Fig. 3).
In the liver, adiponectin has been shown to reduce hepatic glucose production in isolated
hepatocytes (111) by activating AMPK and consequently reducing the expression of
gluconeogenic proteins such as PEPCK and G6Pase (115). Full-length adiponectin can
also enhance fatty acid oxidation in liver slices by increasing the phosphorylation of ACC
in an AMPK-dependent pathway (116) and reduce fatty acid synthesis by suppressing
LKB1/AMPK/SREBP1c pathways (115, 117). However, Yaumachi et al. found that
globular adiponectin cannot activate hepatic AMPK signaling pathways. So the underlying
mechanisms by which globular adiponectin reduces hepatic triglyceride (TAG) are still
unclear (112). Similarly, in the muscle, adiponectin can reduce TAG content and improve
peripheral insulin sensitivity by increasing fatty acid oxidation in an AMPK/ACC dependent
pathway and through modulation of calcium influx (23, 115, 118). An alternative
mechanism proposed to explain adiponectin’s insulin sensitizing effect is by stimulating
ceramidase activity and reducing liver ceramide content, which is independent of AMPK
(114).
However, there are a lot of controversial studies regarding insulin signaling
pathways. For example, numerous studies have dissociated ceramide content from insulin
sensitivity (66, 67, 119, 120), calling into question the physiologic relevance of this finding.
Our study will be critical to clarify those controversies. Furthermore, notably, most of the
mechanistic studies were performed in vitro or ex vivo, lacking in vivo studies that model
physiologic metabolism and the complex stimuli involved in regulating these processes.
20

Furthermore, direct effects of adiponectin on insulin signaling molecules, rates of
endogenous glucose production (EGP), tissue-specific glucose uptake and tissue-specific
rates of mitochondrial oxidation remain poorly investigated. Thus, understanding the
underlying mechanisms of adiponectin would unveil a novel pathway affecting diabetes
susceptibility.
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Figure 3. Schematic representations of the molecular mechanisms by which
adiponectin reduces plasma glucose levels and decreases fat in liver (A) and
skeletal muscle (B).
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Chapter 5
OGT suppresses S6K1-mediated macrophage inflammation and metabolic
disturbance

23

ABSTRACT
Enhanced inflammation is believed to contribute to overnutrition-induced metabolic
disturbance. Nutrient flux has also been shown to be essential for immune cell activation.
Here, we report an unexpected role of nutrient-sensing O-linked β-N-acetylglucosamine
(O-GlcNAc) signaling in suppressing macrophage pro-inflammatory activation and
preventing diet-induced metabolic dysfunction. Overnutrition stimulates an increase in OGlcNAc signaling in macrophages. O-GlcNAc signaling is down-regulated during
macrophage pro-inflammatory activation. Suppressing O-GlcNAc signaling by O-GlcNAc
transferase (OGT) knockout enhances macrophage pro-inflammatory polarization,
promotes adipose tissue inflammation and lipolysis, increases lipid accumulation in
peripheral tissues, and exacerbates tissue-specific and whole-body insulin resistance in
high fat diet-induced obese mice. OGT inhibits macrophage pro-inflammatory activation
by catalyzing ribosomal protein S6 kinase beta-1 (S6K1) O-GlcNAcylation and
suppressing S6K1 phosphorylation and mTORC1 signaling. These findings thus identify
macrophage O-GlcNAc signaling as a homeostatic mechanism maintaining whole-body
metabolism in the setting of overnutrition1.
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INTRODUCTION
Modern global healthcare faces challenges that are different from past generations,
as embodied by the prevalence of obesity worldwide. Obesity and associated insulin
resistance play a pivotal role in the pathogenesis of type 2 diabetes, nonalcoholic fatty
liver disease, atherosclerotic heart disease and other disorders (65, 121). The association
between obesity and the immune system has long been appreciated. The vicious cycle of
inflammation between metabolic organs and immune cells in obese individuals is of major
importance to the development of whole-body insulin resistance and metabolic
dysfunction (122-125). For example, changes in adipose tissue microenvironment caused
by chemokine release, adipocyte death, and other changes. during obesity lead to
macrophage infiltration and pro-inflammatory activation, which further lead to detrimental
effects on insulin action in metabolic tissues and contributes to whole-body insulin
resistance (50, 126, 127). On the other hand, metabolic rewiring has been shown to be
essential for immune cell maturation and acquisition of functional competency (128, 129).
For example, classical (M1-like; pro-inflammatory) activation of macrophages is coupled
to increased glycolysis, reduced mitochondrial oxidative phosphorylation and fragmented
TCA cycle, while alternative (M2-like; anti-inflammatory) activation of macrophages are
characterized by changes in iron metabolism, fatty acid oxidation, glutamine metabolism,
and UDP-GlcNAc pathway (130, 131). Despite the growing knowledge of the function of
immune cells in tissue and whole-body metabolism and an emerging role of metabolic
pathways in immune cell activation and immune responses, how immune cells sense and
integrate nutritional cues and how the nutrient-sensing mechanisms control immune cell
activation and whole-body metabolism remain overarching questions in the field.
O-GlcNAcylation is a nutrient-sensing post-translational modification that involves
the attachment of a single O-linked β-N-acetylglucosamine (O-GlcNAc) moiety to proteins
(132-134). Nutrients including glucose, amino acid, fatty acid, and nucleotide flux into the
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hexosamine biosynthetic pathway (HBP) to generate the donor molecule for OGlcNAcylation, uridine diphosphate GlcNAc (UDP-GlcNAc). A single pair of enzymes, OGlcNAc transferase (OGT) and O-GlcNAcase (OGA), catalyze the addition and removal
of O-GlcNAc moieties from serine and threonine residues of nuclear, cytoplasmic, and
mitochondrial proteins, respectively. O-GlcNAc signaling, the dynamic and reversible
modification in cells, has been shown to fluctuate with the availability of nutrients and
regulate numerous signaling pathways (135-139). Dysregulated O-GlcNAc homeostasis
has been linked to chronic human diseases associated with metabolic dysregulation, such
as obesity, diabetes, cardiovascular diseases, Alzheimer’s disease, and cancer (140-142).
Studies have shown that O-GlcNAcylation dampens insulin signaling both in vitro and in
vivo (134, 135, 143). Key metabolic regulators such as protein kinase B (Akt), forkhead
box protein O1 (FOXO1), carnitine palmitoyltransferase 2 (CPT2) and peroxisome
proliferator-activated receptor-γ coactivator (PGC-1α), can be regulated by OGlcNAcylation (144-147). O-GlcNAcylation was discovered in immune cells over 30 years
ago and has been shown to regulate several immune signaling pathways in vitro, such as
extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), p38 mitogenactivated protein kinase, and nuclear factor κB (NF-κB) signaling pathways (135-137, 148150). However, the function of O-GlcNAc signaling in immune regulation, especially during
metabolic perturbations, remains elusive.
In obesity and insulin resistance, chronic low-grade inflammation develops in
multiple organs such as adipose tissue, liver and skeletal muscle, which is reflected by
immune cell infiltration and elevated pro-inflammatory cytokine production (8, 31, 34, 35,
122, 123, 125). Macrophages are the primary cell type responsible for immune responses
in metabolic tissues (127, 151). Adipose tissue inflammation is characterized by
macrophage infiltration and has been linked to impaired whole-body energy homeostasis
(50, 127, 152). Approximately 10-15% of the stromal cells in adipose tissue are
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macrophages in lean mice, whereas it increases up to 60% of in obese mice (31, 153).
Furthermore, macrophages are capable of acquiring diverse functions in response to
physiological and environmental signals. Classically activated (M1-like) macrophages
produce pro-inflammatory cytokines and promote insulin resistance, while alternatively
activated (M2-like) macrophages produce anti-inflammatory cytokines and are associated
with insulin sensitivity and the lean phenotype (154, 155).
Here, we explored the role of O-GlcNAc signaling in macrophage activation and
metabolic regulation in a mouse model of diet-induced obesity. We observed an increase
in macrophage O-GlcNAc signaling during overnutrition and a transient decrease in OGlcNAc signaling during macrophage pro-inflammatory polarization. Loss of OGT
enhances macrophage pro-inflammatory activation in adipose tissue, which leads to
enhanced adipocyte lipolysis, ectopic lipid accumulation in liver and muscle, and wholebody insulin resistance. These data elucidate an anti-inflammatory role for O-GlcNAc
signaling through inhibiting macrophage pro-inflammatory activation and provide a
molecular link between overnutrition, inflammation and metabolic dysfunction.
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RESULTS
O-GlcNAc signaling is altered during overnutrition and macrophage activation.
To study the nutritional regulation of macrophage function, we first examined how
macrophages respond to different nutrient environments in vitro. Mouse peritoneal
macrophages and bone marrow-derived macrophages (BMDMs) were first maintained in
a culture medium containing physiological (5 mM) glucose and then challenged with 25
mM glucose or 0.3 mM palmitate to mimic glucolipotoxic conditions in type 2 diabetes.
Glucosamine (GlcN) was used as a positive control to boost HBP and O-GlcNAcylation.
Both conditions and GlcN led to enhanced overall O-GlcNAcylation levels, but not OGT
and OGA levels, in cultured macrophages (Fig. 1A and S1A). Moreover, peritoneal
macrophages cocultured with epididymal white adipose tissue (AT) from the high-fat diet
(HFD)-fed mice have increased overall O-GlcNAcylation levels, but not OGT and OGA
levels, as compared to macrophages cocultured with AT from normal chow (NC)-fed mice
(Fig. 1B). These results suggest that overnutrition stimulates an increase of O-GlcNAc
signaling in macrophages in vitro, possibly by boosting the HBP pathway.
We then sought to determine the activity of O-GlcNAc signaling during
macrophage activation. Gene expression profiles retrieved from the Gene Expression
Omnibus repository showed the level of OGT transcripts was decreased by ~20% in
LPS/IFNγ polarized M1-like human macrophages, while no change in OGA transcriptional
level was found (156) (Fig. S1B). To further determine the activation of O-GlcNAc
signaling during macrophage activation, we induced pro-inflammatory M1 [M(LPS)] and
anti-inflammatory M2 [M(IL-4)] polarization by using lipopolysaccharides (LPS) and
interleukin-4 (IL-4) respectively in mouse peritoneal macrophages, BMDMs, and
macrophage cell line RAW 264.7. Consistent with the changes observed in human
macrophages, quantitative real-time PCR (qRT-PCR) analysis showed that OGT
transcriptional level was decreased during LPS-induced M1 polarization but not IL-428

induced M2 polarization, without any difference in OGA transcripts (Fig. 1C and S1C).
Next, we examined the activation of O-GlcNAc signaling at the protein level in BMDMs.
The overall O-GlcNAc modification level was decreased by 25-40% during M1 polarization,
accompanied by a ~45% decrease in the OGT protein level (Fig. 1D and S1D). A transient
elevation of overall O-GlcNAc modification, but no significant changes in OGT and OGA
protein levels, were observed during M2 polarization (Fig. S1E). These results
demonstrate that O-GlcNAc signaling is temporarily suppressed during M1 polarization
and transiently enhanced at the onset of M2 polarization.
We then examined the dynamic changes of overall O-GlcNAcylation levels in
various subpopulations of adipose tissue macrophages during HFD feeding by using flow
cytometry (Fig. 1E, F and S1F-I and S2). F4/80 served as a pan macrophage marker.
CD11c and CD206 were used as markers for M1-like and M2-like macrophages,
respectively. MGL1, highly expressed in resident population of adipose tissue
macrophages, and CCR2, critical for macrophage recruitment to inflammation sites, were
also used as markers (157-159). The results showed that: (1) MGL1+ macrophages
generally have higher overall O-GlcNAcylation levels, as compared to CCR2+
macrophages; (2) CD206+ M2-like macrophages generally have higher overall OGlcNAcylation levels, as compared to CD11c+ M1-like macrophages; (3) Macrophage OGlcNAc signaling is enhanced or maintained at a similar level at the early stage of obesity
(1-week and 4-week HFD feeding) but decreased at the late stage of obesity (12-week
HFD feeding), as compared to the NC-fed mice. Based on these results, we hypothesized
that macrophage O-GlcNAc signaling may have an anti-inflammatory function and
involves in maintaining metabolic homeostasis, especially at the early stage of obesity.
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Figure 1. Nutrient-sensing O-GlcNAc signaling is regulated during overnutrition and
macrophage activation. (A) Western blot analysis of OGT, OGA, and overall OGlcNAcylation levels in mouse peritoneal macrophages after 2 hours treatment. “Vehicle”
was 0.2% BSA and “Ctrl” was culture medium. Glucosamine (GlcN) was used as a positive
control. RL2 recognizes O-GlcNAc modification on proteins. (B) Western blot analysis of
OGT, OGA, and overall O-GlcNAcylation levels in mouse peritoneal macrophages cocultured with epididymal white adipose tissue (AT) of normal chow (NC)-fed and high fat
diet (HFD)-fed mice for 2 hours. (C) Ogt mRNA level in mouse peritoneal macrophages
(peri. MPs), mouse bone marrow-derived macrophages (BMDMs), and RAW 264.7
macrophage cells (n = 4-8). LPS was used to stimulate M1 polarization. (D)
Representative western blots of OGT, OGA and overall O-GlcNAcylation levels in mouse
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BMDMs. LPS was used to stimulate M1 polarization. (E and F) Flow cytometric analysis
of average intensity of O-GlcNAc (RL2) staining of macrophage subpopulations including
F4/80+ CCR2+ cells, F4/80+ MGL1+ cells (E), F4/80+ CD11c+ M1-like macrophages, and
F4/80+ CD206+ M2-like macrophages (F) in the stromal vascular fraction (SVF) of
epididymal white adipose tissue (eWAT) from NC-fed, 1-week HFD-fed, 4-week HFD-fed,
and 12-week HFD-fed WT mice (n = 4-6). Data are shown as mean ± SEM. *p < 0.05, **p
< 0.01, ***p < 0.001 by unpaired Student’s t-test.

31

Figure S1. Macrophage O-GlcNAc signaling is regulated during overnutrition and
macrophage activation. (A) Western blots showing the levels of overall O-GlcNAcylation
(RL2), OGT, OGA, and β-actin in bone marrow derived macrophages (BMDMs) with 0, 2,
8, and 24 hours of incubation with 25 mM glucose (Glc) or 0.3 mM palmitate. (B) Ogt and
Oga mRNA levels in primary human peripheral blood monocytes, cells in the monocytemacrophage differentiation process (In differ.), in vitro differentiated macrophages (MPs),
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and M1- and M2-polarized macrophages (n = 3). Data were retrieved from Gene
Expression Omnibus repository (GSE47122). (C) Oga mRNA levels in mouse peritoneal
macrophages (peri. MPs), mouse bone marrow-derived macrophages (BMDMs), and
RAW 264.7 macrophage cells (n = 4-8). LPS was used to stimulate M1 polarization. (D)
Quantitative analysis of OGT, OGA and overall O-GlcNAcylation levels in mouse BMDMs
as shown in Fig. 1D (n = 3). (E) Representative western blots and quantitative analysis of
OGT, OGA and overall O-GlcNAcylation levels in mouse BMDMs. IL-4 was used to
stimulate M2 polarization (n = 5). (F and G) Flow cytometric analysis of average intensity
of O-GlcNAc (RL2) staining of macrophage subpopulations including F4/80+ CCR2+ cells,
F4/80+ MGL1+ cells, CD11c+ M1-like macrophages, and CD206+ M2-like macrophages in
the stromal vascular fraction (SVF) of inguinal white adipose tissue (iWAT) (F) and
interscapular brown adipose tissue (BAT) (G) from NC-fed, 1-week high fat diet (HFD)fed, 4-week HFD-fed, and 12-week HFD-fed WT mice. (H and I) Statistical analysis of
macrophage subpopulations in the SVF of epididymal white adipose tissue (eWAT) from
NC-fed, 1-week HFD-fed, 4-week HFD-fed, and 12-week HFD-fed WT mice (n = 4-6).
Data are shown as mean ± SEM. ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001 by
one-way ANOVA with Dunnett multiple comparisons for (B), (H) and (I). *p < 0.05, **p <
0.01, ***p < 0.001 by unpaired Student’s t-test for other graphs.
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Figure S2. O-GlcNAcylation level in various subpopulations of adipose tissue
macrophages

during

HFD

feeding.

(A-H)

Gating

strategy

of

macrophage

subpopulations in the SVF of eWAT. Debris (A) and doublet cells (B) were excluded
according to forward scatter profiles (FSC-A) and side scatter profiles (SSC-A and SSCH). Subsequently, Live/Dead Dye staining were used to exclude dead cells (C), and F4/80+
cells were selected (D). Macrophages (F4/80+ cells) were plotted according to MGL1 or
CCR2 expression to show F4/80+ MGL1+ cells (MGL1: a tissue-resident macrophage
marker) (E) and F4/80+ CCR2+ cells (CCR2: an infiltrated macrophage marker) (F).
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Similarly, macrophages were plotted according to CD206 or CD11c expression to identify
F4/80+ CD11c+ cells (CD11c+ M1-like macrophages) (G) and F4/80+ CD206+ cells
(CD206+ M2-like macrophages) (H). (I-L) Representative flow cytometry dot plots of
overall O-GlcNAcylation levels in F4/80+ CCR2+ cells (CCR2 subset) and F4/80+ MGL1+
cells (MGL1 subset) in the SVF of eWAT from NC-fed (I), 1-week HFD-fed (J), 4-week
HFD-fed (K), and 12-week HFD-fed (L) WT mice. (M-P) Representative flow cytometry dot
plots of overall O-GlcNAcylation levels in CD11c+ M1-like macrophages (CD11c subset)
and CD206+ M2-like macrophages (CD206 subset) in the SVF of eWAT from NC-fed (M),
1-week HFD-fed (N), 4-week HFD-fed (O), and 12-week HFD-fed (P) WT mice.
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Macrophage Ogt knockout mice are prone to diet-induced metabolic dysfunction.
To test our hypothesis, we bred the Ogtflox strain with the LysM-Cre transgenic line
to generate a mouse line with Ogt deletion in macrophages and other myeloid cells
(hereafter termed OGT MKO mice) (Fig. S3A-C) and provided them with ad libitum access
to NC and HFD. Flow cytometric analysis showed that OGT KO preferentially affect OGlcNAc signaling in CCR2+ macrophages (Fig. S3D). OGT MKO mice fed NC showed no
difference in body weight, body composition, and whole-body insulin sensitivity compared
to their wild-type (WT) littermates (Fig. S3E-K). We then challenged the mice with HFD.
OGT MKO mice gained slightly more body weight and fat mass compared to their WT
controls after 12 weeks of HFD feeding, which could be attributed to increased food intake
(Fig. 2A, B and S3L). In contrast, there is no difference in lean mass, oxygen consumption
(VO2), respiratory exchange ratio (RER), physical activity and energy expenditure (Fig.
2C and S3M-P). Increases in tissue weights of subcutaneous inguinal white adipose
tissue (iWAT) and interscapular brown adipose tissue (BAT), but not epididymal white
adipose tissue (eWAT), were observed in OGT MKO mice (Fig. S4A-C). Despite an
increase in BAT mass, the core body temperature of OGT MKO mice dropped more
quickly than WT mice during an acute cold challenge (Fig. S4D), which is likely due to
BAT whitening (Fig. S4E).
Whole-body glucose metabolism of HFD-fed WT and OGT MKO mice was
assessed by intraperitoneal glucose tolerance test (GTT), insulin tolerance test (ITT), and
hyperinsulinemic-euglycemic clamps before their body weight diverge (Fig. 2A and S4FH). OGT MKO mice showed a 2-fold increase in plasma insulin levels after overnight
fasting without any significant difference in fasting plasma glucose, non-esterified fatty
acid (NEFA) or triacylglycerol (TAG) concentrations (Fig. S4I-L), reflecting whole-body
insulin resistance. GTT and ITT showed that OGT MKO mice had impaired glucose
metabolism and insulin resistance as compared to WT controls (Fig. S4M-Q), which is
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also illustrated by an increase in the homeostatic model assessment for insulin resistance
(HOMA-IR) (Fig. S4R). During the hyperinsulinemic-euglycemic clamp, OGT MKO mice
exhibited a marked impairment in whole-body insulin sensitivity as reflected by a ~55%
decline in the glucose infusion (GINF) rate required to maintain euglycemia (Fig. 2D and
Fig. S4S, T). Despite no difference in the basal endogenous glucose production (EGP)
rate, the EGP during the clamp was significantly higher in OGT MKO mice (Fig. 2E),
demonstrating impaired hepatic insulin sensitivity. The increased EGP during the clamp
may be attributable to increased acetyl-CoA (Fig. S4U), an allosteric activator of pyruvate
carboxylase (50). We also observed a reduced whole-body glucose turnover rate in OGT
MKO mice (Fig. 2F), which could be at least partially attributed to reduced glucose uptake
in eWAT, BAT, and gastrocnemius muscle (Fig. 2G). Together, these results demonstrate
that loss of macrophage OGT exacerbates diet-induced whole-body insulin resistance
independent of body weight changes.
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Figure 2. OGT MKO mice are prone to diet-induced metabolic dysfunction. (A) Body
weight of HFD-fed WT and OGT MKO mice. (B and C) Fat mass (B) and lean mass (C) of
18-week HFD-fed WT and OGT MKO mice (n = 12-19). (D) Glucose infusion (GINF) rate
to maintain euglycemia during hyperinsulinemic-euglycemic clamps in 8-week HFD-fed
WT and OGT MKO mice. (E and F) Endogenous glucose production (EGP) rate (E) and
whole-body glucose turnover rate (F) in both basal (without insulin stimulation) and clamps
(with insulin stimulation) states in 8-week HFD-fed WT and OGT MKO mice. (G) Glucose
uptake in eWAT, BAT and gastrocnemius muscle under insulin-stimulated condition in 8week HFD-fed WT and OGT MKO mice (n = 5-8). Data are shown as mean ± SEM. *p <
0.05, **p < 0.01, ***p < 0.001 by unpaired Student’s t-test.
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Figure S3. NC-fed OGT MKO mice have normal glucose metabolism, while HFD-fed
OGT MKO have impaired glucose metabolism and increased food intake. (A) The
scheme for generating myeloid cell-specific Ogt knockout (OGT MKO) and wide type (WT)
control mice. (B and C) qRT-PCR (n = 7-12) and western blot analysis showing the mRNA
and protein levels in peritoneal macrophages isolated from WT and OGT MKO mice. (D)
Flow cytometric analysis of average intensity of O-GlcNAc (RL2) staining of F4/80+ CCR2+
cells and F4/80+ MGL1+ cells in the SVFs of eWAT from 12-week HFD-fed WT and OGT
MKO mice (n = 5). (E-G) Body weight (E) (n = 5) and body composition (F and G) (n = 17)
of normal chow (NC)-fed WT and OGT MKO mice. (H-K) Insulin tolerance test (H and I)
and glucose tolerance test (J and K) in NC-fed WT and OGT MKO mice. (L) Average daily
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food intake of 12-week HFD-fed WT and OGT MKO mice. (M-P) Whole-body oxygen
consumption rates (M), respiratory exchange ratios (RERs) (N), physical activities (O),
and energy expenditure (P) of 12-week HFD-fed WT and OGT MKO mice (n = 4). Data
are shown as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired Student’s ttest.
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Figure S4. Impaired BAT function and insulin sensitivity in HFD-fed OGT MKO mice.
(A-C) Tissue weights of inguinal white adipose tissue (iWAT) (A), eWAT (B), and
intrascapular brown adipose tissue (BAT) (C) of 18-week HFD-fed WT and OGT MKO
mice (n = 7-12). (D) Cold challenge test in 12-week HFD-fed WT and OGT MKO mice (n
= 8-14). (E) Hematoxylin and eosin (H&E) staining of BAT from HFD-fed WT and OGT
MKO mice. Scale bar, 20 μm. (F-H) Body weight (F) and body composition (G and H) of
8-week HFD-fed WT and OGT MKO mice. (I and J) Plasma insulin and blood glucose
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concentrations of 8-week HFD WT and OGT MKO mice after overnight fasting (n = 6-14).
(K and L) Plasma non-esterified fatty acid (NEFA) (K) and triglyceride (TAG) (L) levels of
8-week HFD WT and OGT MKO mice after overnight fasting (n = 5-6). (M and N) Plasma
glucose concentrations (M) and AUCglucose (N) during the insulin tolerance test (ITT) in 12week HFD-fed WT and MKO mice. (O-Q) Plasma glucose concentrations (O), AUCglucose
(P) and insulin concentrations (Q) during the intraperitoneal glucose tolerance test (GTT)
in 12-week HFD-fed WT and MKO mice. AUCglucose was calculated using the trapezoidal
rule. (R) Homeostasis model assessment of insulin resistance (HOMA-IR) in 12-week
HFD-fed WT and OGT MKO mice (n = 5-14). (S) Plasma glucose levels during
hyperinsulinemic-euglycemic clamps in 8-week HFD-fed WT and OGT MKO mice (n = 58). (T and U) Plasma insulin concentrations (T) and hepatic acetyl-CoA contents (U) of 8week HFD WT and OGT MKO mice at the end of the hyperinsulinemic-euglycemic clamps
(n = 6). Data are shown as mean ± SEM. *p < 0.05 by unpaired Student’s t-test.
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Loss of macrophage OGT promotes inflammation, adipose tissue lipolysis, and
ectopic lipid accumulation and insulin resistance.
We then assessed the activation of insulin signaling in peripheral tissues of HFDfed WT and OGT MKO mice. The phosphorylation of insulin receptor (IR) kinase and Akt
were reduced in liver, gastrocnemius muscle and eWAT of OGT MKO mice during the
clamp, indicating impaired insulin signaling (Fig. 3A, B and S5A). Ectopic lipid
accumulation is closely associated with insulin resistance (6, 65). To explore the
underlying mechanism of insulin resistance in OGT MKO mice, levels of TAGs and
diacylglycerols (DAGs) in liver and skeletal muscle were determined and the results
showed that OGT MKO mice had a 2-3 fold increase in TAG content in liver and muscle
(Fig. 3C and D). Consistently, a fatty liver phenotype including increased liver weight,
pale-colored liver and histopathologic features of steatosis was observed in OGT MKO
mice (Fig. S5B-E). A 1.5-3 fold increase in DAG content was also found in all tested
compartments (membrane, lipid droplets and cytosol) in both liver and muscle of OGT
MKO mice (Fig. 3E, F and Fig. S5F-I). Previous studies demonstrated that membrane
DAG induces peripheral insulin resistance by promoting the membrane translocation of
PKCε in liver and PKCθ in skeletal muscle (17, 20). Consistently, OGT MKO mice showed
increased PKCɛ translocation from cytosol to the membrane in liver and increased PKCθ
and PKCε translocation in muscle (Fig. 3G-I and Fig. S5J, K). In contrast, no difference
in hepatic and muscle ceramide content was observed (Fig. S5L and M). Taken together,
these data suggest that loss of macrophage OGT promotes diet-induced whole-body
insulin resistance by enhancing ectopic lipid accumulation and activating the DAG-PKC
pathway in liver and skeletal muscle.
Next, we sought to understand the cause of ectopic lipid accumulation in peripheral
tissues of OGT MKO mice. Studies have shown that excessive adipose tissue lipolysis
plays an essential pathogenic role in diet-induced insulin resistance by enhancing fatty
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acid flux into metabolic tissues (50, 160, 161). Consistent with this idea, OGT MKO mice
had increased fatty acid turnover rates during the clamp (Fig. 3J), suggesting that loss of
macrophage OGT impaired insulin suppression of adipose tissue lipolysis. We then
performed an ex vivo lipolysis assay with freshly prepared tissue trunks of WATs from
HFD-fed WT and OGT MKO mice. The results showed that CL-316,243 (a β3-adrenergic
receptor agonist)-stimulated lipolysis was significantly enhanced in sWAT and eWATs of
OGT MKO mice (Fig. 3K and L). To explore the underlying mechanism, we obtained
cultured mature adipocytes differentiated from stromal vascular fraction (SVF) of mouse
eWAT. Then we examined the effects of in vitro cultured WT and OGT KO macrophages
on adipocyte lipolysis in contact (coculture) and non-contact (transwell) manners. The
results showed that both WT and OGT KO macrophages stimulated adipocyte lipolysis in
a cell-cell contact-independent manner. More importantly, compared to WT macrophages,
OGT KO macrophages were more potent to stimulate adipocyte lipolysis (Fig. 3M),
demonstrating an essential role for macrophage OGT in suppressing adipocyte lipolysis
through secreted factors. Previous studies have shown that inflammatory cytokines are
important regulators of adipocyte lipolysis (50, 162). We then determined the levels of proinflammatory cytokines including TNF-α and IL-6 in the serum of 8-week HFD-fed WT and
OGT MKO mice and observed a 3-4 fold increase in OGT MKO mice (Fig. 3N and O).
Further analysis and histological analysis of hematoxylin-eosin (H&E) staining showed
that TNF-α and IL-6 levels were increased by ~25% in eWAT of OGT MKO mice, but no
significant difference in hepatic inflammation (Fig. 3P-S and S5E), showing that adipose
tissue is a primary target of macrophage-induced inflammation. Taken together, these
data indicate that macrophage OGT depletion promotes adipose tissue inflammation and
lipolysis, enhances fatty acid flux into liver and muscle, and finally leads to ectopic lipid
accumulation and DAG-PKC-mediated insulin resistance in these metabolic tissues.
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Figure 3. Loss of macrophage OGT promotes inflammation, adipose tissue lipolysis,
and ectopic lipid accumulation and insulin resistance in liver and muscle
independent of body weight changes. (A) Western blots of insulin-stimulated insulin
receptor (IR) phosphorylation (Y1162) in liver, gastrocnemius muscle and eWAT of 8week HFD-fed WT and OGT MKO mice after overnight fasting. (B) Western blots of
insulin-stimulated Akt phosphorylation (S473) in liver, gastrocnemius muscle and eWAT
of 8-week HFD-fed WT and OGT MKO mice after overnight fasting. (C and D) Triglyceride
(TAG) levels in liver (n = 4) and gastrocnemius muscle (n = 9-11) of 12-week HFD-fed WT
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and OGT MKO mice. (E and F) Membrane diacylglycerol (DAG) levels in liver and
gastrocnemius muscle of 12-week HFD-fed WT and OGT MKO mice (n = 6-14). (G)
Hepatic membrane/cytosolic PKCε ratio in 12-week HFD-fed WT and OGT MKO mice. (H
and I) Membrane/cytosolic PKCθ and PKCε ratio in gastrocnemius muscle of 12-week
HFD-fed WT and OGT MKO mice (n = 5). (J) Whole-body fatty acid turnover of 8-week
HFD-fed WT and OGT MKO mice (n = 6). (K and L) Basal and stimulated (10 μM CL316,243) lipolysis measured by glycerol released from tissue trunks of iWAT (K) and
eWAT (L) of 12-week HFD-fed WT and OGT MKO mice (n = 10-12). (M) Scheme and
glycerol release rate of in vitro cultured adipocyte when co-cultured with WT and OGT KO
peritoneal macrophages in contact (Coculture) and non-contact (Transwell) manners. (NS) TNF-α and IL-6 levels in serum (N and O), eWATs (P and Q) and livers (R and S) of 8week HFD-fed WT and OGT MKO mice. Data are shown as mean ± SEM (n = 5-8). *p <
0.05, **p < 0.01, ***p < 0.001 by two-way ANOVA with Dunnett multiple comparisons for
(K), (L) and (M). *p < 0.05, **p < 0.01 by unpaired Student’s t-test for other panels.
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Figure S5. Increased hepatic steatosis and enhanced liver and muscle insulin
resistance in HFD-fed OGT MKO mice. (A) Western blots of Akt phosphorylation(T308)
in liver, gastrocnemius muscle and eWAT. (B-D) Tissue weights (B) (n = 7-12), images (C)
and H&E staining (D) of liver from 12-week HFD-fed WT and OGT MKO mice. Scale bar,
20 μm. (E) Blinded histological scoring of liver staining to evaluate hepatic steatosis and
liver inflammation and liver injury in 12-week HFD-fed WT and OGT MKO mice. (F-I) DAG
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levels in lipid droplet fraction and cytosolic fraction in liver (F and G) and gastrocnemius
muscle (H and I) of 12-week HFD-fed WT and OGT MKO mice (n = 6-14). (J and K)
Western blots showing levels of PKCε in membrane fraction and cytosolic fraction of liver
(J) and levels of PKCε and PKCθ in membrane fraction and cytosolic fraction of
gastrocnemius muscle (K). (L and M) Ceramide contents in liver (L) and gastrocnemius
muscle (M) of 12-week HFD-fed WT and OGT MKO mice (n = 4-6). Data are shown as
mean ± SEM. *p < 0.05 by Mann-Whitney test for (E). *p < 0.05 by unpaired Student’s ttest for other graphs.
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Loss of macrophage OGT promotes adipose tissue inflammation.
To determine the role of macrophage OGT in adipose tissue inflammation, flow
cytometric analysis of adipose tissue macrophages and macrophage subpopulations was
performed. In WT mice, 12-week HFD feeding induced a 2.5-fold increase of CCR2+
macrophages in eWAT as compared to iWAT, while no difference in MGL1+ macrophages
was found (Fig. S6A and B). Macrophages (F4/80+ cells) comprised 10% of SVF cells in
BAT and 30-40% in iWAT and eWAT (Fig. S6C). In 12-week HFD-fed OGT MKO mice,
a significant increase in the number of total macrophages was found in BAT (~2.5 fold),
but not in iWAT and eWAT, as compared to WT mice (Fig. S6D and S7A). Nevertheless,
a ~2-4 fold increase of F4/80+ CD11c+ macrophages in all examined adipose tissues and
a ~40-50% decrease of F4/80+ CD206+ macrophages in iWAT and eWAT (per gram of
tissue) were observed (Fig. 4A, S6E, F and S7B).
We identified a ~2.5 fold increase in the number of crown-like structures (CLSs)
formed by pro-inflammatory macrophages surrounding necrotic adipocytes in the wholemount adipose tissue staining of iWAT and eWAT from OGT MKO mice (Fig. 4B and C),
which is consistent with enhanced accumulation of pro-inflammatory CD11c+ M1-like
macrophages in WATs of OGT MKO mice. qRT-PCR analysis showed that the expression
of macrophage pro-inflammatory polarization markers, Il-6 and Nos2, was increased in
various adipose tissues of OGT MKO mice compared with WT mice, without difference in
Arg1 expression, an M2 polarization marker (Fig. 4D, E and S7C). These data
demonstrate that loss of macrophage OGT aggravates adipose tissue inflammation by
promoting pro-inflammatory macrophage activation and/or infiltration, which may
contribute to increased WAT lipolysis.
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Figure 4. Loss of macrophage OGT promotes adipose tissue inflammation. (A)
Quantification of flow cytometric analysis of F4/80+ CD11c+ cells in BAT, iWAT and eWAT
from 12-week HFD-fed WT and OGT MKO mice (n = 4). (B) Whole-mount staining of iWAT
and eWAT of 12-week HFD-fed WT and OGT MKO mice showing adipocytes (BODIPY
FL, stains lipids) and macrophages (CD11c+ cells) in crown-like structures (CLSs). Scale
bar, 80 μm. (C) Quantitative results of CLSs in iWAT and eWAT of 12-week HFD-fed WT
and OGT MKO mice (n = 6). (D and E) Nos2 and Il-6 mRNA levels in BAT, iWAT, and
eWAT of 12-week HFD-fed WT and OGT MKO mice (n = 4-8). Data are shown as mean
± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired Student’s t-test.
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Figure S6. HFD-fed OGT MKO mice have enhanced accumulation of M1-like
macrophages in adipose tissue as compared with HFD-fed WT mice. (A-C) Flow
cytometric analysis of macrophage subpopulations including F4/80+ CCR2+ cells (A),
F4/80+ MGL1+ cells (B), and overall macrophages (F4/80+ cells) (C) in the SVF of eWAT,
iWAT, and BAT from NC-fed, 1-week HFD-fed, 4-week HFD-fed, and 12-week HFD-fed
WT mice (n = 4-6). (D) Representative flow cytometry dot plots showing macrophages
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(F4/80+ cells) in SVF of adipose tissue from HFD-fed WT and OGT MKO mice. (E and F)
Representative dot plots showing CD11c+ cells and CD206+ cells gated through F4/80+
cells shown in (D).
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Figure S7. O-GlcNAc signaling is involved in macrophage M1 polarization, but not
M2 polarization. (A and B) Quantification of flow cytometric analysis of macrophages
(F4/80+ cells) and CD206+ M2-like macrophages in the SVF of BAT, iWAT and eWAT from
12-week HFD-fed WT and OGT MKO mice. (C) Arg1 mRNA level in BAT, iWAT, and
eWAT of 12-week HFD-fed WT and OGT MKO mice (n = 4). (D) Nos2, Ccl2, TNF-α, and
pro-Il-1b mRNA levels in WT and OGT KO BMDMs. IFN-γ was used to stimulate M1
polarization. (E) Arg1, Clec10, Chi3l3, and Retnla mRNA levels in WT and OGT KO
BMDMs. IL-4 was used to stimulate M2 polarization (n = 6). (F) Nos2 and Il-6 mRNA levels
in DMSO-, thiamet-G (TMG)-, 6-Acetamido-6-deoxy-castanospermine (6-Ac-Cas)-, and
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PUGNAc-treated RAW 264.7 cells under unstimulated and LPS-stimulated conditions. (G)
Nos2 and Il-6 mRNA levels in Myc-, Myc-OGT-, and Myc-OGT-CD-overexpressing RAW
264.7 cells under unstimulated and LPS-stimulated conditions (n = 3). (H) Western blots
showing levels of overall O-GlcNAcylation (RL2), OGT, and β-actin of BMDMs
overexpressing Myc, Myc-OGT and Myc-OGT-CD (D925N). Data are shown as mean ±
SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by two-way ANOVA with Dunnett multiple
comparisons for (F) and (G). *p < 0.05, **p < 0.01 by unpaired Student’s t-test for other
panels.
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O-GlcNAc signaling suppresses macrophage pro-inflammatory activation.
Based on the above results, we hypothesized that O-GlcNAc signaling plays a
suppressive role in macrophage pro-inflammatory activation. M1-like polarized
macrophages are known to exhibit an elongated and spreading morphology with
pseudopod-like protrusions (163). LPS-induced peritoneal macrophage activation was
analyzed and we defined the spread cells as “activated cells” and the round-shaped cells
as “resting cells” (Fig. 5B). Bright-field imaging showed that OGT KO group had a 2-3 fold
increase in the percentage of activated cells, as compared to the WT group, under both
unstimulated and LPS-stimulated (30 minutes) conditions (Fig. 5A-C), suggesting loss of
OGT accelerates and promotes LPS-induced macrophage pro-inflammatory activation.
We then treated WT and OGT KO BMDMs with fluorescein-labeled zymosan particles and
found that OGT KO BMDMs internalized ~75% more zymosan particles compared to WT
BMDMs (Fig. 5D-F), suggesting loss of OGT enhances macrophage phagocytic activity.
Finally, qRT-PCR analysis showed that loss of OGT enhanced the expression of LPSinduced M1 markers including Nos2, Ccl2, TNF-α, and Il-6 or pro-Il-1b by 100-200% and
IFN-γ- induced M1 markers by 50-100% (Fig. 5G and S7D), but had no effect on IL-4induced M2 markers expression including Arg1, Clec10a, Chi3l3, and Retnla (Fig. S7E).
Together, these data demonstrate a specific role of OGT in suppressing macrophage proinflammatory polarization.
To gain further insight into the role of O-GlcNAc signaling in macrophage proinflammatory polarization, O-GlcNAc signaling was interrogated in BMDMs and RAW
264.7 cells by treatment with various OGA inhibitors: thiamet-G (TMG), 6-Acetamido-6deoxy-castanospermine (6-Ac-Cas) and PUGNAc. The results showed that the
pharmacological inhibition of OGA suppressed the expression of LPS-induced M1
markers, Nos2 and Il-6, by 40-60% (Fig. 5H and S7F). Consistent with this finding, OGT
overexpression suppressed LPS-induced Nos2 and Il-6 expression by 40-60%, while
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overexpression of the dominant negative OGT catalytic dead mutant (OGT-CD, D925N)
significantly enhanced LPS-induced Nos2 and Il-6 expression (Fig. 5I and S7G, H). Taken
together, these results demonstrate a suppressive role of O-GlcNAc signaling in
macrophage pro-inflammatory activation.
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Figure 5. O-GlcNAc signaling suppresses macrophage pro-inflammatory activation.
(A-C) Bright field imaging and statistical analysis of unstimulated and LPS-stimulated
activation of peritoneal macrophages isolated from WT and OGT MKO mice (n = 4-8).
Scale bars, 20 μm. (D-F) Fluorescence imaging and statistical analysis of phagocytosis of
zymosan particles by WT and OGT KO BMDMs. Scale bar, 20 μm. (G) Macrophage M1
marker Nos2, Ccl2, TNF-α, and Il-6 mRNA levels in un-stimulated and LPS-stimulated WT
and OGT KO BMDMs (n = 3-6). (H) Nos2 and Il-6 mRNA levels in DMSO-, thiamet-G
(TMG)-, 6-Acetamido-6-deoxy-castanospermine (6-Ac-Cas)-, and PUGNAc-treated
BMDMs under unstimulated and LPS-stimulated conditions (n = 6). (I) Nos2 and Il-6
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mRNA levels in Myc-, Myc-OGT-, and Myc-OGT-CD-overexpressing BMDMs under
unstimulated and LPS-stimulated conditions (n = 4). Data are shown as mean ± SEM. *p
< 0.05, **p < 0.01, ***p < 0.001 by two-way ANOVA with Dunnett multiple comparisons for
(C), (H), and (I). *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired Student’s t-test for other
panels.
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RNA sequencing analysis reveals a preferential regulation of macrophage proinflammatory polarization by OGT.
Macrophage activation involves extensive transcriptional rewiring (130). To assess
the role of OGT in the systemic reprogramming during macrophage activation, we
performed RNA sequencing-based transcriptional profiling for unstimulated (M0), LPSstimulated (M1) and IL-4-stimulated (M2) WT and OGT KO BMDMs. Overall, the heat map
of differentially expressed genes (DEGs) showed that loss of OGT led to a significantly
increased expression of a large set of genes and a decreased expression of a small set
of genes in M0, M1 and M2 polarized BMDMs (Fig. 6A). These results demonstrate a
prevalent role of OGT in suppressing macrophage activation at the transcriptional level.
Strikingly, DEGs between WT and OGT KO BMDMs in M0 and M2 groups shared a similar
expression pattern, whereas DEGs in the M1 group showed a very unique pattern (Fig.
6A). Venn diagram showing the overlap of DEGs between every two groups also support
the same conclusion (Fig. S8A). Then all three groups of DEGs were overlaid with a group
of genes identified as macrophage-related genes (164, 165). Nine DEGs were found to
be present in all groups, suggesting a robust OGT-mediated regulation of these genes.
Again, a larger set of macrophage-related DEGs were found to be specifically present in
the M1 group (57 in M1 vs. 19 in M2 and 14 in M0) (Fig. S8B). Together, these results
suggest that OGT in macrophages preferentially regulates macrophage M1 polarization,
which is consistent with our previous results showing that loss of OGT affects LPS- and
IFN-γ- induced M1 polarization but not IL-4-induced M2 polarization (Fig. 5G and S7D,
E). The expression of selected M1 and M2 markers determined by RNA sequencing were
also analyzed. Consistent with the previous results, loss of OGT enhanced the expression
of M1 markers in LPS-treated BMDMs but did not affect the expression of M2 markers in
IL-4-treated BMDMs (Fig. 6B and S8C).
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Gene set enrichment analysis (GSEA) for the Gene Ontology terms showed that
loss of OGT in M1-polarized BMDMs enhanced the expression of genes that are highly
enriched in the following GO terms: cytokine production, regulation of cytokine production,
defense response, positive regulation of multicellular process, and immune response (Fig.
S8D), supporting a role of OGT in suppressing macrophage M1 activation and
inflammation. Genes enriched in GO terms including myeloid cell differentiation and
myeloid leukocyte differentiation were down-regulated in M1-polarized OGT KO BMDMs
(Fig. S8D). To determine whether macrophage maturation is affected by OGT, qRT-PCR
analysis was performed and similar levels of F4/80, a macrophage marker, was observed
in WT and OGT KO BMDMs (Fig. S8E), demonstrating that LyzM-Cre-mediated OGT KO
does not affect monocyte-macrophage differentiation. GSEA comparing M1- and M2activated pathways between WT and OGT KO BMDMs showed that two pathways,
inflammatory response and signaling receptor binding, were significantly enhanced in M1polarized OGT KO BMDMs (Fig. S8F and G), suggesting that OGT may suppress
macrophage M1 polarization by inhibiting signaling pathways involved in an inflammatory
response.
To provide additional insights into the mechanism by which OGT regulates
macrophage M1 polarization, top DEGs between WT and OGT KO BMDMs in the M1
group were shown in a Volcano plot (Fig. 6C). Among the top up-regulated DEGs in OGT
KO BMDMs, genes closely related to M1 polarization including Il12b, Ccl22, Nos2, Ifng,
Ccr7, and Ifnb1 were found. A large portion of the up-regulated DEGs including Clic5,
Dnase1l3, Kynu, Adra2b, Rasgrf1, Tspan10, Dll4, Hamp, and Gpihbp1 have been known
to play important roles in macrophage M1 polarization. Also, a small set of genes known
to be involved in macrophage regulation including Mmp9, Dcstamp, Cyp2s1, and Mgat5b
were identified in the top down-regulated DEGs (Fig. 6C). Together, these results
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demonstrate a profound role of OGT-mediated transcriptional rewiring in the suppression
of macrophage pro-inflammatory polarization.
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Fig. 6. RNA sequencing analysis reveals a preferential regulation of macrophage M1
polarization by OGT. (A) Heat map showing the differentially expressed genes (DEGs)
between WT and OGT KO BMDMs, where colors indicate counts per million (cpm) values
scaled by row (n =4). (B) Heat maps of expression levels of M1 macrophage markers
determined by RNA sequencing. (C) Volcano plot showing top DEGs between M1polarized WT and OGT KO BMDMs. Red dot-labelled genes are up-regulated in OGT KO
BMDMs and are closely related to M1 polarization. Purple and green dot-labelled genes
have known functions related to M1 polarization and are up- and down-regulated in OGT
KO BMDMs, respectively.
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Figure S8. RNA sequencing analysis of M1- and M2-polarized WT and OGT KO
BMDMs. (A) Venn diagram showing the overlap of DEGs (between WT and OGT KO
BMDMs) between different polarization groups (M0 and M2; M0 and M1; and M2 and M1).
(B) Venn diagram showing the overlap among DEGs (between WT and OGT KO BMDMs)
from different polarization groups and macrophage-related genes. (C) Heat maps of
expression levels of M2 macrophage markers determined by RNA sequencing. (D) Gene
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set enrichment analysis (GSEA) of DEGs between M1-polarized WT and OGT KO
BMDMs for Gene Ontology terms. x axis indicates –log10-transformed p-values of GSEA,
multiplied by +1 and -1 for up- and down-regulated pathways, respectively. (E) F4/80
mRNA levels in in vitro differentiated WT and OGT KO BMDMs (n = 6). (F and G) Heat
maps showing the differentially regulated biological (F) and molecular (G) pathways in M1and M2-polarized WT and OGT KO BMDMs, where cell colors in the heatmap show –
log10-transformed p-values of GSEA, multiplied by +1 and -1 for up- and down-regulated
pathways, respectively. The most up-regulated pathway in each analysis was marked with
a red box over the heatmap.
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mTORC1/S6K1 signaling.
To understand the molecular mechanism by which O-GlcNAc signaling
suppresses pro-inflammatory macrophage activation, we assessed the activation of
several signaling pathways essential for macrophage pro-inflammatory polarization in WT
and OGT KO BMDMs. We observed loss of OGT significantly enhanced LPS-induced
activation of mTORC1/ribosomal protein S6 kinase beta-1 (S6K1) and NF-κB signaling
but not the activation of ERK, JNK, AKT, and p38 signaling (Fig. 7A). Moreover, TMG
treatment suppressed LPS-induced S6K1 activation in BMDMs (Fig. S9A). To determine
the role of NF-κB and mTORC1/S6K1 signaling in OGT-mediated macrophage proinflammatory polarization, we first treated WT and OGT KO BMDMs with PF-04708671
(S6K1 inhibitor) and rapamycin (mTORC1 inhibitor), and then with LPS to induce proinflammatory M1 polarization. qRT-PCR analysis showed that blocking mTORC1/S6K1
signaling, but not NF-κB signaling, completely abolished the enhancement of Nos2 and Il6 expression in OGT KO macrophages upon LPS stimulation, suggesting that OGT
suppresses macrophage M1 polarization by inhibiting mTORC1/S6K1 pathway (Fig. 7B,
C and S9B-E).
To determine how OGT regulates mTORC1 signaling, we first tested if tuberous
sclerosis complex 2 (TSC2), a key regulator of mTORC1 signaling, can be modified by OGlcNAcylation. Our previous proteome-wide analysis of OGT-binding proteins in HEK
293T cells showed that TSC2 is among the 853 putative OGT-binding proteins (145) (Fig.
S9F). However, we were not able to detect any notable O-GlcNAcylation on TSC2, even
in OGT-overexpressing cells (Fig. S9G). Moreover, the levels of TSC2 phosphorylation
on multiple sites were not changed in OGT KO macrophages (Fig. S9H), suggesting that
OGT may not affect TSC2 activity. S6K1 is a major mTORC1 downstream signaling
molecule. A previous study showed that ribosomal protein S6 kinase-like 1 (S6LK), which
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shares ~40% homology with S6K1, can be modified by O-GlcNAcylation (166). We
observed a robust interaction between exogenous OGT and S6K1 in HeLa cells and RAW
264.7 cells (Fig. 7D and S10A). OGT overexpression in HeLa cells and RAW 264.7 cells
led to enhanced O-GlcNAcylation and decreased serine phosphorylation on S6K1 (Fig.
7E and S10B), indicating a competition between S6K1 O-GlcNAcylation and
phosphorylation. We then sought to identify the glycosylation sites on S6K1. Based on a
list of potential O-GlcNAcylation sites predicted by two independent online computational
prediction analyses (167, 168), a series of S6K1 single-site mutants were generated and
how these mutations affect overall S6K1 O-GlcNAcylation was determined. The results
showed that the mutation of serine 489 to alanine (S489A) largely eliminated overall S6K1
O-GlcNAcylation in HeLa cells and RAW 264.7 cells (Fig. 7F and S10C-E), indicating that
serine 489 is the primary site for S6K1 O-GlcNAcylation.
To establish the functional relevance of S6K1 O-GlcNAcylation in macrophage
activation, we examined the effect of S6K1 O-GlcNAcylation on S6K1 phosphorylation in
RAW 264.7 cells. The results showed that eliminating S6K1 serine 489 O-GlcNAcylation
enhanced S6K1 phosphorylation at serine 418 and threonine 229 (Fig. 7G), supporting
the notion that loss of S6K1 O-GlcNAcylation at serine 489 promotes S6K1
phosphorylation at the C-terminus autoinhibitory domain, which further facilitates
phosphorylation and activation of its N-terminal kinase domain (169-171). Consistently,
LPS-induced pro-inflammatory M1 polarization was enhanced by 40-70% in RAW 264.7
cells overexpressing HA-S6K1-S489A mutation, as compared to HA- and HA-S6K1overexpressing cells (Fig. 7H, and S10F-H). These studies indicate that OGT suppresses
macrophage

pro-inflammatory

polarization

by

GlcNAcylation/phosphorylation and S6K1 activation (Fig. 7I).
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Figure 7. OGT inhibits macrophage pro-inflammatory polarization by suppressing
mTORC1/S6K1 signaling. (A) Western blot analysis showing the activation of S6K1, NFκB, ERK, JNK, p38 MAPK, AKT in unstimulated and LPS-stimulated (30 minutes) WT and
OGT KO peritoneal macrophages. (B and C) Nos2 and Il-6 mRNA levels in unstimulated,
LPS-stimulated, and PF-04708671-pretreated LPS-stimulated WT and OGT KO BMDMs
(n = 4). (D) Immunoprecipitation (IP) and western blot analysis showing the interaction
between exogenously expressed HA-S6K1 and Myc-OGT in HeLa cells. (E) IP and
western blot analysis showing that OGT overexpression enhances S6K1 O-GlcNAcylation
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and decreases S6K1 serine phosphorylation in HeLa cells. (F) IP and western blot
analysis showing that serine 489 to alanine (S489A) mutation in S6K1 greatly abolished
the overall O-GlcNAcylation on S6K1 in HeLa cells. (G) IP and western blot analysis
showing that S489A mutation in S6K1 enhanced LPS-induced S6K1 phosphorylation on
Threonine 229 (T229) and S418 in RAW 264.7 cells. (H) Nos2 mRNA levels in untreated
and LPS-stimulated RAW 264.7 cells overexpressing HA, HA-S6K1 and HA-S6K1-S489A
(n = 4-6). (I) Molecular model for OGT function in mTORC1/S6K1 signaling. Data are
shown as mean ± SEM. **p < 0.01 by two-way ANOVA with Dunnett multiple comparisons
for (H). **p < 0.01, ***p < 0.001 by unpaired Student’s t-test for other panels.
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Figure S9. Suppressing NF-κB signaling does not rescue the enhanced M1
polarization in OGT KO macrophages. (A) Western blot analysis of S6K1 and its
phosphorylation in untreated and TMG-pretreated BMDMs. LPS treatment (30 minutes)
was used to stimulate M1 polarization. (B and C) Nos2 and Il-6 mRNA levels in
unstimulated, LPS-stimulated, and rapamycin (Rapa)-pretreated LPS-stimulated WT and
OGT KO peritoneal macrophages (n = 4-8). (D and E) Nos2 and Il-6 mRNA levels in
unstimulated, LPS-stimulated, and BMS-345541-pretreated LPS-stimulated WT and OGT
KO peritoneal macrophages. BMS-345541, an IκB kinase inhibitor, was used to inhibit NFκB signaling (n = 6). (F) Intensities of Tuberin (TSC2) binding to OGT under various
conditions determined by our proteome-wide analysis of OGT-binding proteins in HEK
293T cells. (G) Immunoprecipitation (IP) and western blot analysis showing no interaction
was found between exogenously expressed Flag-TSC2 and Myc-OGT in HEK 293T cells.
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(H) Western blot analysis of TSC2 and its phosphorylation in unstimulated and LPSstimulated (30 minutes) WT and OGT KO peritoneal macrophages. Data are shown as
mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired Student’s t-test.
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Figure S10. OGT inhibits macrophage pro-inflammatory polarization by regulating
S6K1. (A) IP and western blot analysis showing the interaction between exogenously
expressed HA-S6K1 and Myc-OGT in RAW 264.7 cells. (B) IP and western blot analysis
showing that OGT overexpression enhances S6K1 O-GlcNAcylation and decreases S6K1
serine phosphorylation in RAW 264.7 cells. (C) Statistical analysis showing that serine
489 to alanine (S489A) mutation in S6K1 largely abolished the overall O-GlcNAcylation
on S6K1 in HeLa cells (n = 3). (D and E) IP (D) and statistical analysis (E) showing that
S489A mutation in S6K1 greatly abolished S6K1 O-GlcNAcylation in RAW 264.7 cells (n
= 3). (F) S6K1 mRNA level in RAW 264.7 cells with ectopically expressed HA, HA-S6K1
and HA-S6K1-S489A (n = 4). (G and H) Il-6 and TNF-α mRNA levels in untreated and
LPS-stimulated RAW 264.7 cells overexpressing HA tag, HA-S6K1 and HA-S6K1-S489A
(n = 4-6). Data are shown as mean ± SEM. *p < 0.05, **p < 0.01 by one-way ANOVA with
Dunnett multiple comparisons for (F). **p < 0.01, ***p < 0.001 by two-way ANOVA with
Dunnett multiple comparisons for other graphs.
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DISCUSSION
In this study, we demonstrate that macrophage O-GlcNAc signaling plays a
profound role in suppressing adipose tissue inflammation and insulin resistance. Recent
studies have expanded our knowledge about the functional and molecular integration of
metabolic and inflammatory pathways. Hyperglycemia and energy surplus associated with
obesity and metabolic syndrome have been shown to promote inflammatory responses
through various mechanisms (172, 173). Changes in glucose uptake, glycolysis, and UDPGlcNAc biosynthesis were observed during macrophage polarization (130, 131).
Additionally, free fatty acids have been shown to activate inflammatory pathways and
impair insulin action in adipose tissue (174). These findings prompted us to postulate that
nutrient-sensing O-GlcNAc signaling serves as a link between overnutrition and insulin
resistance by regulating macrophage function in metabolic tissues. However, only few
studies have attempted to directly evaluate the role of O-GlcNAc signaling in macrophage
activation and contradictory results were reported (175-177). Here, using in vitro and in
vivo models, we demonstrate that O-GlcNAc signaling suppresses macrophage proinflammatory M1-like polarization and is dispensable for anti-inflammatory M2-like
polarization, which supports an immunosuppressive role of O-GlcNAc signaling in
macrophage activation.
Increasing evidence has established a causative link between pro-inflammatory
macrophage and insulin resistance in both rodents and human (50, 155). Previous studies
have shown that suppressing macrophage pro-inflammatory activation or entirely
depleting the macrophage population is protective against diet-induced metabolic
dysregulation (178, 179). Consistent with this, we found that genetic ablation of OGT in
macrophages results in increased adipose tissue inflammation and excessive adipose
tissue lipolysis, thus leading to increases in ectopic lipid accumulation and whole-body
insulin resistance. Our study provides compelling evidence for the existence of a
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protective mechanism against inflammation through O-GlcNAc signaling in obesity. OGlcNAc signaling enables macrophages to sense external nutrients and restrains
macrophage pro-inflammatory activation, which contributes to adipose tissue and wholebody metabolic homeostasis. We speculate that macrophage O-GlcNAc signaling is part
of a homeostatic mechanism maintaining metabolic homeostasis at the early stage of
obesity. However, pro-inflammatory stimuli, such as adipocyte cell death and proinflammatory cytokines secreted by other cells, are aggravated by prolonged HFD feeding.
Eventually, the protective mechanism is pushed to the limit and becomes dysfunctional in
severely obese animals. Consistent with this idea, a study showed that pro-inflammatory
macrophages in mouse epididymal fat appear 3 weeks after the initiation of HFD feeding.
In contrast, the accumulation of neutrophils peaks at day 3 after initiating HFD feeding
(180). These results suggest that the pro-inflammatory activation of macrophages is
inhibited at an early stage of exposure to excess amounts of nutrients.
mTOR signaling lies at the core of nutrient-sensing and inflammatory pathways
(181). Previous studies implicate that TSC1, an upstream regulator of mTORC1,
orchestrates macrophage M1 and M2 activation via separate pathways. Loss of TSC1
promotes M1-like activation by stimulating the ERK pathway, while inhibiting M2-like
activation by suppressing the ERK and C/EBPβ pathways (182, 183). Several studies
have suggested that obesity is associated with increased mTOR activity, and deficiency
of the downstream mediator S6K1 can protect mice against diet- and age-induced insulin
resistance (184, 185). The current study has identified OGT as a key regulator of the
mTOR/S6K1 pathway. We have shown that O-GlcNAcylation suppresses mTORC1
signaling by directly regulating S6K1. S6K1 O-GlcNAcylation inhibits sequential
phosphorylation required for kinase activation, resulting in suppression of proinflammatory gene transcription. Suppression of mTORC1/S6K1 pathway abrogates the
effect of OGT deletion on LPS-induced M1 activation, suggesting that S6K1 is integral to
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OGT-mediated macrophage regulation. Therefore, our study provides novel mechanistic
insight

into

the

regulation

and

the

function

of

mTORC1/S6K1

pathway

in

immunometabolism.
Macrophages display considerable plasticity with M1 and M2 activation states at
two extremes. How macrophages acquire diverse activation states in response to
metabolic cues is still largely unknown. A previous study showed that mTOR/MYC
signaling enhances O-GlcNAc signaling by promoting OGT protein expression (186). The
AMP-activated protein kinase (AMPK) pathway is the other nutrient-sensing pathway
involved in macrophage polarization, and AMPK can negatively regulate the mTOR
pathway (187). Furthermore, there is evidence that O-GlcNAcylation of AMPK regulates
its enzymatic activity (188). Taken together, it is likely that OGT, mTORC1 and AMPK
pathways form a complex nutrient-sensing network that underpins a spectrum of
macrophage activation states.
In summary, this study demonstrates O-GlcNAc signaling as a novel homeostatic
regulator at the interface of inflammation and metabolism. The results have important
implications for our understanding of the integration of metabolism and immunity, an
evolutionary need for survival (189). Future studies to explore how macrophage O-GlcNAc
signaling integrates nutritional signals to dictate the immune response would help develop
new immunomodulatory strategies to treat chronic metabolic diseases. Glutamine and
glucosamine, the popular nutritional supplements implicated in immunometabolism, both
are known to fuel the hexosamine biosynthetic pathway and promote O-GlcNAc signaling.
Studies have shown that human adipose glutamine levels correlate inversely with fat mass
and white fat inflammation (190). Glutamine supplementation attenuates adipose tissue
inflammation and reduces metabolic risk in rodents (190, 191). Supplementing
glucosamine in HFD-fed rats improves glucose metabolism and reduces visceral fat mass
(192). Further investigation is warranted to determine whether O-GlcNAc signaling in
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immune cells is involved in these processes. It is worth noting that glucosamine also
protects against sepsis-induced tissue injury and septic death in mouse and zebrafish
models (177). Therefore, the immunosuppressive function of O-GlcNAc signaling may
have broader implications in both obesity-associated morbidity and immune-related
diseases.
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METHODS
Animals
Ogtflox mice were crossed with LyzM-Cre mice to generate Ogtflox LyzM-Cre-/- (WT)
and Ogtflox LyzM-Cre+/- (OGT MKO) mice. Ogtflox mice were described previously (193)
and were kindly provided by Dr. Steven Jones at the University of Louisville. LyzM-Cre
mice were from The Jackson Laboratory (Catalog No. 004781). All mice were housed in
a 12 h: 12 h light-dark cycle at 25 °C. Unless otherwise specified, mice were free to access
water and food and were maintained on a normal chow diet. High fat fed mice were given
ad libitum access to a high fat diet (D12492, Research Diets) when they were 6-9 weeks
old. Male mice were used for the experiments. All animal experiments were performed in
accordance with protocols approved by Yale University’s Institutional Animal Care and
Use Committee. Body weights were recorded every week. Body composition was
measured by nuclear magnetic resonance relaxometry using an EchoMRI system. Freshly
dissected tissues were used to determine tissue weights. For metabolic cage analysis,
single-housed mice were first acclimated in metabolic chambers for 3 days. Then gas
exchange, energy expenditure, and physical activity were recorded for 4 days. Average
daily food intake of each mouse was measured by weighing the food every day at the
same time continuously for 3 days.

Biochemical Analyses
Blood glucose concentrations were measured by using a Nova Max Glucometer
or the YSI 2700 Select Biochemistry Analyzer. Plasma insulin concentrations were
measured by ELISA (Millipore) or radioimmunoassay (Millipore). Plasma non-esterified
fatty acid (NEFA) and triglyceride concentrations were measured by using a Wako kit and
the Sekisui triglyceride-SL reagent respectively. Serum inflammatory cytokine (IL-6 and
TNF-α) concentrations were measured by ELISA (BD OptEIA) assay.
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Tissue Analyses
Liver and skeletal muscle triglyceride contents were measured as previously
described (194). Briefly, lipids were extracted from liver and gastrocnemius muscle using
2:1 chloroform:methanol and measured by using the Sekisui triglyceride-SL reagent
spectrophotometrically. Tissue acetyl-CoA, diacylglycerols, and ceramide concentrations
were measured by liquid chromatography/mass spectrometry/mass spectrometry (LCMS/MS) (19, 50, 195). For the measurement of inflammatory cytokine (IL-6 and TNF-α)
levels, tissues were first homogenized in PBS and then centrifuged at 4°C to obtain
supernatant. The supernatants were then analyzed by ELISA (BD OptEIA) assay.

Glucose tolerance test and insulin tolerance test
For glucose tolerance test, mice were fasted overnight and injected
intraperitoneally with a single dose of glucose (1.5 g/kg body weight), then tail-vein blood
was taken at designated times and blood glucose levels were determined using a Nova
Max Glucometer. For insulin tolerance test, mice were fasted for 6 hours in the morning
and injected intraperitoneally with a single dose of insulin (1 U/kg body weight for all NCfed mice and 1.5 U/kg body weight for all HFD-fed mice), then blood glucose levels were
measured as described above.

Basal and hyperinsulinemic-euglycemic clamp study
An indwelling catheter was placed in the jugular vein seven days before the clamp
study. Mice were fasted overnight the day before the study. To measure whole-body
lipolysis, a 120 minutes basal infusion with [3-3H] glucose (HPLC purified; PerkinElmer)
and [13C16] potassium palmitate (Cambridge Isotopes) was performed as described (50).
Blood was collected from the tail vein at 120 minutes. After the basal period, a 140-minute
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hyperinsulinemic-euglycemic clamp was performed by infusing a continuous rate of insulin
(10 mU/[kg-min] for 3 minutes and 3 mU/[kg-min] for 140 minutes) and variable rates of
20% dextrose to maintain euglycemia along with the infusion of [13C16] sodium palmitate,
while periodic tail vein blood sampling was performed. In the last 55 minutes of the clamp
period, 10 μCi 2 deoxy-[1-14C] glucose (2-DG) was injected to measure tissue-specific
glucose uptake. At 140 minutes, a final blood sample was collected and the mice were
euthanized by intravenous injection of sodium pentobarbital. Liver, gastrocnemius muscle,
white and brown adipose tissues were freeze-clamped in pre-cooled in liquid nitrogen and
stored at -80 °C for further analyses.

Flux measurements
The specific activity of [3-3H] glucose in plasma samples collected at the steady
state during basal and clamp study was measured by using a liquid scintillation counter
as previously described (50). During basal, endogenous glucose production (EGP) is the
only source of glucose appearance whose rate equals to glucose turnover rate at steady
state, therefore EGP = glucose turnover rate. During clamp, EGP and glucose infusion
together contribute to glucose appearance, therefore EGP = glucose turnover rate glucose infusion rate. [13C16] palmitate enrichments were measured using gas
chromatography-mass spectrometry (GC/MS) as previously described (196). Palmitate
turnover = ([13C16] palmitate tracer enrichment/[13C16] palmitate plasma enrichment-1) x
infusion rate. The fatty acid turnover was measured by correcting for the percentage of
palmate in total fatty acids (197).

Cold challenge
For thermogenesis studies, single-housed mice were transferred from room
temperature to 4 °C for 6 hours. Core body temperature was examined in conscious mice
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using a rectal thermometer. During this process, food was removed but the mice had free
access to water and the bedding material was left in the cage.

Cell culture and treatments
All cells were cultured at 37 °C in 5% CO2. RAW 264.7, HeLa, and HEK 293T cells
were from the American Type Culture Collection and were cultured in DMEM (GIBCO)
supplemented with 10% FBS (GIBCO). Plasmids were transfected into cells by using
FuGENE HD (Promega) or jetPEI-Macrophage (Polyplus-transfection). For primary
adipocyte culture, the stromal vascular fraction (SVF) of the mouse epididymal white fat
was isolated, cultured and differentiated into adipocytes as described previously (198).
Murine resident peritoneal macrophages and bone marrow-derived macrophages
(BMDMs) were isolated and generated as described (199). To test the effects of OGA
inhibitors, macrophages were pretreated with 10 μM TMG, 6-Ac-Cas, or PUGNAc for 6
hours. Then LPS was added (in the presence of OGA inhibitors) to stimulate M1
polarization. Similarly, PF-04708671 (1 μM), BMS-345541, and rapamycin (100 nM) were
added 1 hour prior to the LPS treatment.

Macrophage polarization and phagocytosis assay
BMDMs and peritoneal macrophages were treated with LPS (100 ng/ml, unless
specified otherwise) to induce M1 polarization. A higher concentration of LPS (1 μg/ml)
was used to induce M1 polarization in RAW 264.7 cells. IL-4 (10 ng/ml) was used to induce
M2 polarization in BMDMs and peritoneal macrophages. Unless otherwise stated,
macrophages were collected 30 minutes later for cell signaling analysis or 12 hours later
for qRT-PCR analysis. For the phagocytosis assay, BMDMs were cultured in M-CSF-free
medium for 24 hours and then incubated with opsonized fluorescently labeled zymosan A
bioparticles (Thermo Fisher) for 1 hour at 37°C. Then phagocytosis was stopped by adding
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cold PBS. BMDMs were washed, fixed, and counterstained with DAPI for fluorescence
microscopy.

Quantitative real-time PCR and RNA-seq
Total RNA was isolated from untreated, LPS-treated, and IL-4-treated (12 hours
unless otherwise stated) WT and OGT KO BMDMs using TRIzol Reagent (Invitrogen).
Then total RNA samples were used for cDNA synthesis (iScript cDNA Synthesis Kit) and
SYBR Green-based quantitative real-time PCR analysis (Bio-Rad). The level of 36b4 was
used as internal control. Primer sequences are: 36b4-F (5’-AGATGCAGCAGATCCGCAT3’), 36b4-R (5’-GTTCTTGCCCATCAGCACC-3’); Ogt-F (5’AAGAGGCACGCATTTTTGAC-3’), Ogt-R (5’-ATGGGGTTGCAGTTCGATAG-3’); Oga-F
(5’-CTCAGAGGCTGAGAAAATAATGTTGAG-3’), Oga-R (5’AAGGGAAGTTGGCAAGGAAAGT-3’); Nos2-F (5’-TTCTGTGCTGTCCCAGTGAG-3’),
Nos2-R

(5’-TGAAGAAAACCCCTTGTGCT-3’);

Il6-F

(5’-

GAGGATACCACTCCCAACAGACC-3’), Il6-R (5’-AAGTGCATCATCGTTGTTCATACA3’); TNF-α-F (5’-CATCTTCTCAAAATTCGAGTGACAA-3’), TNF-α-R (5’TGGGAGTAGACAAGGTACAACCC-3’); Ccl2-F (5’-ATTGGGATCATCTTGCTGGT-3’),
Ccl2-R (5’-CCTGCTGTTCACAGTTGCC-3’); pro-Il1b-F (5’AAGAGCTTCAGGCAGGCAGTATCA-3’),

pro-Il1b-R

(5’-

ATGAGTCACAGAGGATGGGCTCTT-3’); Arg1-F (5’-TTTTTCCAGCAGACCAGCTT-3’),
Arg1-R (5’-AGAGATTATCGGAGCGCCTT-3’); Clec10-F (5’CTCTGGAGAGCACAGTGGAG-3’), Clec10-R (5’-ACTTCCGAGCCGTTGTTCT-3’);
Retnla-F (5’-CTGGATTGGCAAGAAGTTCC-3’), Retnla-R (5’CCCTTCTCATCTGCATCTCC-3’); Chi3l3-F (5’-TTTCTCCAGTGTAGCCATCCTT-3’),
Chi3l3-R (5’-TCTGGGTACAAGATCCCTGAA-3’). For RNA-seq, total RNA was isolated
by using the RNeasy Plus Mini Kit (QIAGEN). RNA integrity was examined by
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electrophoresis for quality control purpose. Then the RNA samples were used to generate
eukaryotic transcriptome libraries. The sequencing was performed on the HiSeq PE-150
platform with 30m reads. For RNA-seq analysis, total RNA-seq reads were mapped to
iGenome UCSC MM10 gene annotation using TopHat (200) version 2.1.0. Mapped reads
were summarized for each gene using HTSeq (201) version 0.9.1. Differential expression
analysis was implemented using edgeR (202, 203) version 3.22.5 with FDR = 0.05 and at
least 1 absolute log2 fold change. Gene set enrichment analysis was implemented using
the

ToppGene

Suite

(https://toppgene.cchmc.org/).

Western blotting and immunoprecipitation
Cells were lysed in lysis buffer containing 1% Nonidet P-40, 50 mM Tris-HCl, 150
mM NaCl, 0.1 mM EDTA together with proteinase inhibitors and protein phosphatase
inhibitors. Protein lysates were then denatured by heating in laemmli sample buffer
containing SDS and β-mercaptoethanol, resolved by SDS-PAGE, and transferred to
PVDF membranes (Millipore). The membranes were blocked with 5% skimmed milk or
bovine serum albumin (BSA), incubated with primary antibodies first, and then with
horseradish peroxidase-conjugated secondary antibodies (Cell Signaling Technology).
Proteins were visualized with ECL western blotting substrate (Pierce). For protein kinase
Cε (PKCε) and PKCθ translocation, cytoplasm and plasma membrane fractions were
separated by ultracentrifugation as previously described (67, 71). For immunoprecipitation,
cell lysates were incubated with antibody-conjugated agarose beads at 4 °C overnight.
The beads were then washed and boiled in laemmli sample buffer, and the proteins were
examined by western blotting.

Reagents and plasmids
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Antibodies against O-GlcNAc [RL2] (ab2739), phosphoserine [PSR-45], NaKATPase [464.6] and OGA (EPR7154(B)) (Abcam); OGT (D1D8Q), JNK1 (2C6), phosphoJNK (81E11), phospho-Akt (Ser473) (587F11), phospho-Akt (Thr308) (244F9), Akt (9272),
phospho-p38 (D3F9), phospho-ERK 1/2 (D13.14.4E), ERK 1/2 (137F5), phospho-TSC2
(Thr1462) (3611), phospho-TSC2 (Ser1387) (D2R3A), phospho-TSC2 (Ser939) (3615),
TSC2 (D93F12), phospho-IR (Y1162) (3024), IR (3020), and GAPDH (14C10) (Cell
Signaling Technology); S6K1 (DK7994), phospho-S6K1 (Thr229) (DK7994), phosphoS6K1 (Ser371) (DK3904), and phospho-S6K1 (Ser418) (AC0176) (eBioscience); NF-κB
p65 (A-12), and p-NF-κB p65 (Ser 536), and Myc (9E10) (Santa Cruz Biotechnology); Flag
(M2), HA (H3663), and β-actin (A5441) (Sigma-Aldrich); PKCε (610086) and PKCθ
(610090) (BD Bioscience) were purchased from the indicated sources. PF-04708671,
BMS-345541, and rapamycin (Cayman Chemical), TMG (Carbosynth), and PUGNAc
(Sigma-Aldrich) were from indicated sources. LPS (B5S-36-01, InvivoGen), mouse IL-4
(5208, Cell Signaling Technology), IFN-γ (2728403, Millipore), and rmM-CSF (416-ML,
R&D Systems) were from the indicated sources. Mammalian expression plasmids pCMVMyc-hOGT and catalytic dead pCMV-Myc-hOGT-G598S (catalytic dead) were described
and kindly provided by Dr. Xiaochun Yu at the University of Michigan. pRK7-HA-S6K1WT encoding HA-tagged rat S6K1 was from Addgene (Plasmid #8984). HA-S6K1 mutants
were generated using QuikChange II site-directed mutagenesis kit (Agilent).

Lipolysis assay
For white adipose tissue ex vivo lipolysis assay, freshly dissected adipose tissue
was cut into small explants (~3 mm diameter), washed in PBS, and transferred to KrebsRinger buffer with 3 mM HEPES and 1% free fatty acid-free BSA and incubated in a 37 °C
shaker. Media samples were collected at selected time points. The amount of free glycerol
released into the medium was measured using the Free Glycerol Reagent (Sigma-Aldrich).
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To determine lipolysis in cultured adipocytes, SVFs of the mouse epididymal white fat
were isolated and differentiated into mature adipocytes as previously described (198).
Peritoneal macrophages were plated directly on top of the adipocytes or in a transwell (0.4
μM pore size) inserted into the adipocyte culture medium. The macrophages were
stimulated with LPS (100 ng/ml, 30 minutes) and then the cells were washed with PBS
and incubated in phenol red-free medium. The amount of released glycerol was
determined by using the Free Glycerol Reagent (Sigma-Aldrich).

Flow cytometry
For flow cytometry analysis, SVFs of mouse adipose tissues were isolated as
described previously (198). In brief, mouse adipose tissue was dissected and minced into
fine pieces on ice. Then, adipose tissues were digested to get single cell suspensions.
Digestion buffer and mature adipocytes were removed by centrifugation. The pellets were
collected, resuspend in FACS buffer (1X DPBS, 2 mM EDTA, and 1% FBS), filtered
through 70 μm filters, and centrifuged again to obtain SVFs. Generally, 1×106 cells were
used for staining. For cell surface marker staining, the following fluorochrome-conjugated
antibodies from Biolegend were added: F4/80 (BM8, 1:200 dilution), CD11c (N418, 1:100),
CD206 (C068C2, 1:100), MGL1 (LOM-8.7, 1:200), CCR2 (SA203G11, 1:200), and
CD16/CD32 (Fc block, 93, 1:1000). Zombie NIR™ Fixable Viability Kit (Biolegend) was
used to determine live cells. If intracellular staining for O-GlcNAcylation was required, cells
were then fixed and permeabilized by using Fixation/Permeabilization Solution Kit
(Biosciences). Cells were then washed and incubated with AlexaFluor 647-conjugated OGlcNAc antibody (RL2, Novus Biologicals, 1:800). Stained SVFs were filtered through 40
μm filters and analyzed by a BD LSRII flow cytometer. The results were analyzed by using
FlowJo.
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Histology
Animals were sacrificed and tissues were collected, fixed (4% paraformaldehyde,
overnight at 4 °C), dehydrated, and embedded in paraffin. Tissue sections were then
prepared by using a microtome and stained with hematoxylin-eosin (H&E) staining.
Blinded histological scoring of liver slides was performed by an experienced pathologist.

Whole-mount adipose tissue staining
To visualize macrophages in adipose tissue, freshly prepared whole mounted
adipose tissue (~4 mm x 4 mm x 2 mm) was fixed in a mild fixative (1% paraformaldehyde,
30 minutes), penetrated in a mild detergent buffer (0.5% Tween 20, 30 minutes), and
stained with Alexa Fluor 647-conjugated anti-CD11c antibody (N418, BioLegend),
BODIPY FL, and DAPI. The stained tissue was mounted and imaged as described (204).

Statistical analysis
Data were plotted and statistically evaluated using GraphPad Prism version 7.0a
(GraphPad Software). Results were presented as mean ± SEM. Two-condition
comparisons

were

performed

using

unpaired

two-tailed

Student’s

t-test.

For

nonparametric comparison of means, Mann-Whitney test was used. For multipleconditions comparisons, one-way or two-way ANOVA with Dunnett multiple comparisons
was used. Differences that are statistically significant were plotted as p < 0.05 (∗), p < 0.01
(∗∗), and p < 0.001 (∗∗∗).
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Chapter 6
Mechanisms by Which Adiponectin Reverses High Fat Diet-induced Insulin
Resistance in Mice
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ABSTRACT
Adiponectin has emerged as a potential therapy for type 2 diabetes mellitus, but
the molecular mechanism by which adiponectin reverses insulin resistance remains
unclear. Two-weeks of globular adiponectin (gAcrp30) treatment reduced fasting plasma
glucose, triglyceride (TAG) and insulin concentrations and reversed whole-body insulin
resistance, which could be attributed to both improved insulin-mediated suppression of
endogenous glucose production and increased insulin-stimulated glucose uptake in
muscle and adipose tissues. These improvements in liver and muscle sensitivity were
associated with reductions in liver and muscle TAG and plasma membrane (PM)
associated diacylglycerol (DAG) content and occurred independently of reductions in total
ceramide content. Reductions of PM DAG content in the liver and skeletal muscle were
associated with reduced PKCε translocation in liver and reduced PKCθ and PKCε
translocation in skeletal muscle resulting in increased insulin-stimulated insulin receptor
tyrosine1162 phosphorylation, IRS-1/IRS-2-associated PI3-kinase activity and Akt-serine
phosphorylation. Both gAcrp30 and full-length adiponectin (Acrp30) treatment increased
eNOS/AMPK activation in muscle and muscle fatty acid oxidation. gAcrp30 and Acrp30
infusions also increased plasma triglyceride uptake in eWAT, which could be attributed to
increased lipoprotein lipase (LPL) activity. These data suggest that adiponectin and
adiponectin-related molecules reverse lipid-induced liver and muscle insulin resistance by
reducing ectopic lipid storage in these organs resulting in decreased membrane DAGinduced nPKC activity and increased insulin signaling. Adiponectin mediates these effects
by both promoting the storage of plasma triglyceride in eWAT likely through stimulation of
LPL, as well as by stimulation of AMPK in muscle resulting in increased muscle fat
oxidation.2

2

Other contributors to this work include Dongyan Zhang, Daniel F. Vatner, Leigh Goedeke, Sandro
M. Hirabara, Ye Zhang, Rachel J. Perry, and Gerald I. Shulman
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is one of the leading causes of morbidity and
mortality in the adult population worldwide (82, 205) and is associated with disease in
many organ systems, including nonalcoholic fatty liver disease (NAFLD) and
atherosclerotic vascular disease (ASCVD) (5-7, 84). Insulin resistance plays a critical role
in the pathogenesis of T2DM and metabolic syndrome. The adipokine adiponectin has
emerged as a potential anti-diabetic, anti-inflammatory and anti-atherogenic factor (23,
24). Unlike adipokines such as leptin, plasma adiponectin levels are inversely correlated
with adiposity and decreased in obesity, insulin resistance and T2DM (108, 109).
Adiponectin is present in human plasma as full-length adiponectin (Acrp30) and as a Cterminal globular fragment (gAcrp30) (110, 118, 206). The C-terminal globular fragment is
produced by proteolytic cleavage and is thought to be the pharmacologically active moiety
(110). A wide variety of explanations for adiponectin's glucose-lowering and insulinsensitizing properties has been proposed, which have been derived predominantly from
in vitro and ex vivo studies, including: suppression of gluconeogenesis (111, 115, 207);
increased 5' AMP-activated protein kinase (AMPK)/ acetyl-CoA carboxylase (ACC)dependent fatty acid oxidation in liver and muscle (23, 115, 118, 208); and reduced hepatic
ceramide content by activation of hepatic ceramidase (114). A clear, consistent model for
adiponectin’s action in vivo is lacking, and the mechanisms by which adiponectin
ameliorates insulin resistance are a matter of active debate.
The association between ectopic lipid and insulin resistance in the liver and
skeletal muscle is widely recognized (13-15). Diacylglycerols (DAGs) and ceramides are
the two best-studied mediators of lipid-induced insulin resistance. Ceramides have been
shown to impair insulin action at the level of protein kinase B (Akt) phosphorylation,
through activation of protein kinase Cζ (PKCζ) and/or protein phosphatase 2A (81, 209,
210). In contrast, plasma membrane sn-1,2-DAGs, which has been shown to be the key
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DAG stereoisomer, impair insulin action via activation of novel PKCs (nPKCs), including
PKCε in liver (17, 18, 66) and both PKCθ and PKCe in skeletal muscle (68, 211). PKCe
activation subsequently impairs insulin receptor kinase (IRK) tyrosine kinase activity and
PKCq activation impairs insulin signaling at the level of IRS-1/IRS-2 associated PI3-kinase
activity (14, 19, 20). Insulin resistance in the liver leads to reduced insulin-stimulated
hepatic glycogen synthesis and defects in insulin suppression of hepatic glucose
production, while insulin resistance in the skeletal muscle leads to reduced insulinstimulated muscle glucose transport. In the setting of white adipose tissue (WAT) insulin
resistance, WAT lipolysis is resistant to suppression by insulin, leading to increased nonesterified fatty acid (NEFA) delivery to the liver and muscle, which may further promote
increased liver and muscle ectopic lipid content (6, 7, 161, 212).
Given that prior studies have demonstrated that increased plasma adiponectin
concentrations lead to accretion of WAT and improved glycemia in mice (213, 214), we
hypothesized that the insulin-sensitizing properties of adiponectin might be due to
protection against ectopic lipid deposition in insulin-responsive tissues. To address this
hypothesis, we performed a comprehensive series of studies to assess the effects of twoweek gAcrp30 and Acrp30 treatment on multiple metabolic fluxes using a combination of
stable- and radio-labeled isotopic tracers, in a high fat diet (HFD)-fed mouse model of
lipid-induced insulin resistance. Here, we demonstrate that two weeks of gAcrp30
treatment reverses whole-body insulin resistance in HFD-fed mice by reducing plasma
membrane DAG content, resulting in decreased translocation of PKCε to the plasma
membrane in liver and decreased PKCε/ PKCθ translocation in skeletal muscle leading to
increased insulin signaling in both of these tissues. This reduction in ectopic lipid storage
in liver and muscle could be attributed to increased lipoprotein lipase activity in epididymal
WAT (eWAT), resulting in increased lipid uptake in eWAT, as well as activation of AMPK
in muscle, which in turn promoted increased fatty acid oxidation in skeletal muscle. Taken
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together, these results provide new insights into the mechanisms by which adiponectin
reverses insulin resistance in vivo.
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RESULTS
Two-week globular adiponectin treatment ameliorates lipid-induced insulin
resistance
In order to examine the effect of long-term exposure to increased globular
adiponectin (gAcrp30) on glucose metabolism, we performed continuous subcutaneous
gAcrp30 infusions (2.5μg/day) in 12-week HFD-fed mice for two weeks. As expected,
plasma adiponectin concentrations increased in the gAcrp30-treated mice compared with
control mice (Fig. 1A). To assess the effect of gAcrp30 on energy balance, metabolic
cages were utilized and whole-body energy expenditure was determined by indirect
calorimetry. Consistent with the lack of difference in body weight or body composition (Fig.
1B and 1C), we observed no effect of gAcrp30 on whole-body oxygen consumption,
carbon dioxide production, energy expenditure, caloric intake, respiratory exchange ratio,
drinking or activity (Fig. 1D-1J).
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Figure 1. Two-week adiponectin treatment has no effect on whole-body energy
metabolism of control and gAcrp30-treated mice. (A) Plasma adiponectin
concentrations after overnight fasting in HFD-fed mice treated with globular adiponectin
(gAcrp30) or vehicle-control for two weeks. (B) Body weight of control and gAcrp30treated mice (n = 9-11). (C) Fat mass of control and gAcrp30-treated mice. (D) Wholebody oxygen consumption. (E) Whole-body carbon dioxide production. (F) Whole-body
energy expenditure. (G) Whole-body caloric intake. (H) Whole-body respiratory exchange
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ratio. (I) Drinking. (J) Activity Counts. Data are shown as mean ± SEM. **p < 0.01 by
unpaired Student’s t-test for other panels.
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While gAcrp30 did not alter whole-body energy metabolism, plasma triglyceride
(TAG) concentrations as well as liver TAG content and muscle TAG content were
significantly reduced by 35%, 45% and 60% respectively (Fig. 2A-2C). Consistent with a
reduction in ectopic lipid content in liver and skeletal muscle, mice treated for two weeks
with gAcrp30 exhibited a 10% reduction in plasma glucose concentrations and a 65%
reduction in plasma insulin concentrations after overnight fasting (Fig. 2D and 2E). In
contrast, there was no difference in fasting plasma NEFA concentration between groups
(Fig. 2F). In order to determine the effects of gAcrp30 on tissue-specific insulin action, we
performed hyperinsulinemic-euglycemic clamps combined with radiolabeled and stable
isotopes. Basal endogenous glucose production (EGP) was reduced by 13% in the
gAcrp30 group as compared with the control group (Fig. 2G), resulting in reduced fasting
plasma glucose concentrations (Fig. 2D). During the hyperinsulinemic phase of the clamp
study, gAcrp30-treated mice displayed a two-fold increase in the glucose infusion rate
required to maintain euglycemia, reflecting increased whole-body insulin-sensitivity (Fig.
2H-2J). The increased whole-body insulin sensitivity could be attributed to both a 2-fold
increase in insulin-mediated suppression of hepatic glucose production, and a 15%
increase in insulin-stimulated peripheral glucose disposal (Fig. 2G, 2K and Fig. 2L).
Specifically, our data demonstrated that glucose uptake is increased by 50-100% in all
assessed tissues, including skeletal muscle, WAT and brown adipose tissue (Fig. 2M2O).
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Figure 2. Globular adiponectin treatment ameliorates lipid-induced insulin
resistance in high-fat diet (HFD) fed mice. (A) Plasma triglyceride concentrations of
control and gAcrp-30 treated mice after overnight fasting. (B)-(C) Liver and muscle
triglyceride content of control and gAcrp-30 treated mice. (D)-(E) Plasma glucose (n = 10)
and insulin concentrations (n = 4-5) of control and gAcrp-30 treated mice after overnight
fasting. (F) NEFA under basal and hyperinsulinemic-euglycemic conditions. (G)
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Endogenous glucose production rate under basal and the hyperinsulinemia-euglycemia
clamp states (n = 8-10). (H) Glucose infusion rate during the hyperinsulinemic-euglycemic
clamp. (I) Glucose concentrations during the hyperinsulinemia-euglycemia clamp of
control and gAcrp-30 treated mice. (J) Insulin concentrations after the hyperinsulinemiaeuglycemia clamp. (K) Endogenous glucose production rate suppression during the
hyperinsulinemia-euglycemia

clamp.

(L)

Glucose

turnover

rate

during

the

hyperinsulinemia-euglycemia clamp. (M)-(O) Insulin-stimulated glucose uptake rate in
skeletal muscle, white adipose tissue and brown adipose tissue in control and gAcrp30treated mice. Data are shown as mean ± SEM. *p < 0.05, **p < 0.01 by two-way ANOVA
with Dunnett multiple comparisons for (F) and (G). *p < 0.05, **p < 0.01, ***p < 0.001 by
unpaired Student’s t-test for other panels.
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Globular adiponectin reduces plasma membrane DAG content and nPKC activation
in liver and skeletal muscle
As two weeks of gAcrp30 treatment resulted in a marked improvement in liver and
muscle insulin sensitivity, we next assessed insulin signaling pathways in the liver and
skeletal muscle of these mice. Consistent with increased whole-body insulin sensitivity,
gAcrp30 treated mice manifested 2 to 4-fold increases in insulin-mediated insulin receptor
tyrosine autophosphorylation (tyrosine 1162) in both liver and skeletal muscle (Fig. 3A
and 3B). We also observed four-fold increases in insulin-stimulated insulin receptor
substrate-2 (IRS-2) associated phosphoinositide 3-kinase (PI3K) activity in liver and IRS1 associated PI3K activity in muscle, as well as two-fold increases in Akt2 phosphorylation
in liver and skeletal muscle of gAcrp30 treated mice as compared with vehicle-treated
mice in the clamp state (Fig. 3C-3F), indicating improved insulin signaling in liver and
muscle. Activated c-Jun N-terminal kinase (JNK) can phosphorylate insulin receptor
substrate-1 (IRS-1) serine 302, resulting in negative regulation of the insulin signaling
pathway in mouse tissues (23, 215). This mechanism may play a role in the improved
insulin sensitivity seen in gAcrp30 treated mice, as we observed an ~40% decrease in
JNK phosphorylation in liver and muscle from animals treated with gAcrp30 vs. vehicletreated animals (Fig. 3G and 3H), which may in part be due to adiponectin’s effect on
reducing oxidative stress (23).
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Figure 3. Globular adiponectin increases insulin signaling at the level of insulin
receptor kinase in liver and skeletal muscle. (A)-(B) Western blot images for insulin
receptor kinase phosphorylation (pY1162) in liver (n = 5-7) and skeletal muscle (n = 5) of
control and gAcrp30-treated mice under the hyperinsulinemic-euglycemic clamp
condition. Quantification is shown below. (C) IRS-2 associated PI3K activity in liver. (D)
IRS-1 associated PI3K activity in muscle (n = 5). (E)-(F) Western blot images for Akt
phosphorylation (pS473) in liver (n = 5-7) and skeletal muscle (n = 5) in the clamp state.
Quantification is shown below. (G) Representative western blot images for JNK
phosphorylation in liver of control and gAcrp30-treated mice in the clamp state.
Quantification is shown below. (H) Western blot images for JNK phosphorylation skeletal
muscle (n = 5) in the clamp state. Quantification is shown below. Data are shown as mean
± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 by unpaired Student’s t-test.

97

DAGs and ceramides are two well-studied bioactive lipids that have been proposed
to mediate lipid-induced insulin resistance (66). Plasma membrane DAGs have been
shown to mediate insulin resistance by activation of nPKCs, specifically PKCε in the liver
and both PKCε and PKCθ in the skeletal muscle (17, 19, 216, 217). Among the three
stereoisomers of DAG (sn-1,2-DAG, sn-1,3-DAG and sn-2,3-DAG), sn-1,2-DAG is thought
to be primarily responsible for nPKC activation (218-220). To understand the mechanism
by which gAcrp30 treatment ameliorates lipid-induced liver and muscle insulin resistance,
DAG content, ceramide content and nPKC translocation were measured in these tissues.
Hepatic plasma membrane sn-1,2-DAG was decreased by 35% in gAcrp30-treated mice,
which was associated with an ~50% reduction in PKCε membrane translocation, reflecting
reduced PKCε activation (Fig. 4A and 4B). Plasma membrane sn-2,3-DAG content was
decreased by 35% without any difference in sn-1,3-DAG content and sn-1,2-DAG content
in other subcellular compartments (Fig. 4A, 4C and 4D). INSR Thr1160 is a PKCε target,
upon which phosphorylation impairs the tyrosine kinase activity of the insulin receptor, and
thereby diminishes downstream insulin signaling (17, 219). Consistent with reductions in
PKCe activity and improved hepatic insulin sensitivity, hepatic insulin receptor Thr1160
phosphorylation was decreased in gAcrp30-treated mice (Fig. 4E). Similarly, in the
gastrocnemius muscle, gAcrp30-treated mice exhibited a ~55% reduction in plasma
membrane DAG content with an associated 60-80% reduction in PKCθ and PKCε
translocation (Fig. 4F-4H). In contrast, despite the reductions in liver and muscle TAG
content, plasma membrane DAG content and marked reversal of insulin resistance in liver
and skeletal muscle, there were no significant changes in total ceramide content in these
tissues (Fig. 5A and 5B), arguing against an important role for adiponectin-induced
activation of ceramidase as the insulin sensitizing mechanism by which adiponectin would
have been expected to lead to a reduction in total ceramide content (114). In addition, we
did not observe any significant differences in the total content of specific ceramide species
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(C16:0 and C18:0) which have been specifically hypothesized to mediate insulin
resistance in rodents (78, 221) (Fig. 5C-5F). While gAcrp30 treatment did not cause a
reduction in total tissue ceramide content, it did result in reductions in several hepatic
ceramide species (C16:0, C20:0, C22:0, C24:0 and C24:1) in the plasma membrane (Fig.
5G), which correlated with the improved insulin sensitivity in liver.
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Figure 4. Globular adiponectin reduces tissue membrane DAG content and nPKC
activation in liver and muscle. (A) Hepatic sn-1,2-DAG content in five subcellular
compartments (ER: endoplasmic reticulum; LD: lipid droplets; PM: plasma membrane;
Mito: mitochondrial; Cyto: cytosol). (B) Hepatic membrane/cytosolic PKCε ratio.
Quantification is shown below. (C) Hepatic sn-2,3-DAG in five subcellular compartments.
(D) Hepatic sn-1,3-DAG in five subcellular compartments. (E) Western blot images for
insulin receptor kinase phosphorylation (pY1160) in liver (n = 5). Quantification is shown
below. (F) Membrane DAG content in skeletal muscle. (G)-(H) Membrane/cytosolic PKCθ
and PKCε ratio in skeletal muscle. PKCθ and PKCε were probed from the same
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membrane and therefore have the same corresponding loading controls (GAPDH and
Na/K-ATPase). Quantification is shown below. Data are shown as mean ± SEM. *p < 0.05,
**p < 0.01 by two-way ANOVA with Dunnett multiple comparisons for (A), (C) and (D). *p
< 0.05, **p < 0.01 by unpaired Student’s t-test.
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Figure 5. Globular adiponectin did not significantly affect total ceramide content but
changes several plasma membrane ceramide species. (A)-(B) Total ceramide content
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compartments (ER: endoplasmic reticulum; LD: lipid droplets; PM: plasma membrane;
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Mito: mitochondrial; Cyto: cytosol). Data are shown as mean ± SEM. *p < 0.05, **p < 0.01
by unpaired Student’s t-test for other panels.
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gAcrp30 improves insulin signaling in white adipose tissue
Next, we sought to understand the effect of gAcrp30 treatment on insulin signaling
in WAT and on WAT lipolysis. gAcrp30 administration increased phosphorylation of IRK
and Akt2, and reduced phosphorylation of perilipin, adipose triglyceride lipase (ATGL) and
hormone-sensitive lipase (HSL) in the clamp state, indicating improved insulin signaling in
WAT (Fig. 6A-6E). Consistent with these data, gAcrp30-treated mice had reduced wholebody glycerol turnover rate in the basal and clamp state, demonstrating that gAcrp30
treatment reduced WAT lipolysis and improved insulin signaling in WAT (Fig. 6F).
Reduced glycerol conversion to glucose may result in reduced hepatic glucose production
and plasma glucose concentrations (222). However, surprisingly there were no differences
in the whole-body fatty acid turnover rate or plasma non-esterified fatty acids (NEFA)
concentrations (Fig. 6G and 2F), suggesting that gAcrp30 may also promote WAT reesterification. Consistent with the lack of differences in fatty acid turnover, we observed
no differences in hepatic acetyl-CoA, malonyl-CoA, or long-chain acyl-CoA concentrations
(Fig. 6H-6G). Taken together, these data indicate that gAcrp30 treatment also improves
insulin signaling in WAT and may affect WAT lipolysis and re-esterification.
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Figure 6. gAcrp30 improves insulin signaling in white adipose tissue and may affect
WAT lipolysis and re-esterification. (A) Western blot images for insulin receptor kinase
phosphorylation (pY1162) in white adipose tissue (n = 5-6) in the clamp state.
Quantification is shown below. (B) Western blot images for Akt phosphorylation (pS473)
in white adipose tissue (n = 5-6) in the clamp state. Quantification is shown below. (C)-(E)
Western blot images for perilipin, hormone-sensitive lipase (HSL) and adipose triglyceride
lipase (ATGL) phosphorylation in white adipose tissue (n = 5-6) in the clamp state.
Quantification is shown below. (F) Glycerol turnover rate under basal and
hyperinsulinemic-euglycemic conditions (n = 5-7). (G) Fatty acid turnover rate under basal
and hyperinsulinemic-euglycemic conditions (n = 5). (H)-(J) Basal hepatic acetyl CoA,
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Malonyl CoA and Long-chain acyl CoA concentrations. Data are shown as mean ± SEM.
*p < 0.05, **p < 0.01 by two-way ANOVA with Dunnett multiple comparisons for (F) and
(G). *p < 0.05, **p < 0.01 by unpaired Student’s t-test for other panels.
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Globular adiponectin treatment promotes a switch from glucose to fat oxidation in
slow-twitch gastrocnemius and soleus muscles
In order to determine whether the reduction in ectopic lipid (TAG/DAG) content
could be attributed to increased fatty acid oxidation in liver and muscle, we assessed
mitochondrial function in vivo and ex vivo. We employed positional isotopomer NMR tracer
analysis (PINTA) to assess the effects of gArcp30 on in vivo hepatic citrate synthase flux
(VCS, i.e. mitochondrial oxidation) and hepatic pyruvate carboxylase flux (VPC, i.e.
gluconeogenesis from pyruvate) (223) and observed no significant differences in hepatic
VPC or VCS in gAcrp30 treated mice (Fig. 7A and 7B). In addition, there was no difference
in the phosphorylation of two key regulators of hepatic fatty acid oxidation and
biosynthesis: AMPK and ACC with gAcrp30 treatment (Fig. 7C and 7D). In summary, no
differences were observed in hepatic mitochondrial oxidation rate or its upstream
regulators or downstream outflow (VPC) in the gAcrp30 treated mice.
Relative rates of mitochondrial ketone oxidation and β-oxidation (VFAO) normalized
to citrate synthase flux (VCS) were determined in vivo in multiple tissues. gAcrp30
treatment promoted a shift away from glucose to other substrates (fatty acids, ketones,
ketogenic amino acids) in gastrocnemius muscle (Fig. 7E), despite no effect on liver or
quadriceps muscles (Fig. 7F and 7G). To further examine the effects of gAcrp30 on
absolute rates of fatty acid oxidation and glucose oxidation in muscle, we assessed rates
of 14CO2 production in isolated soleus muscle with [1-14C]palmitic acid and [14C6]D-glucose
as substrates. Consistent with the in vivo gastrocnemius data, both fatty acid oxidation
and glucose oxidation were increased in the Acrp30-treated and gAcrp30-treated soleus
muscles (Fig. 7H and 7I). To understand the potential molecular mechanisms by which
fatty acid oxidation was increased in the soleus muscle, we measured phosphorylation of
AMPK, ACC and endothelial nitric oxide synthase (eNOS). Previous studies have shown
that there is a positive feedback loop between nitric oxide production and AMPK activation
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(224). Consistent with these studies, we observed significant increases in phosphorylation
of AMPK, ACC and eNOS in the skeletal muscle of both Acrp30-treated and gAcrp30treated mice (Fig. 7J-7L). These data suggest that gAcrp30 and Acrp30 treatment
activates the eNOS/AMPK/ACC pathway and promotes a switch from glucose oxidation
to fatty acid oxidation in predominately slow-twitch gastrocnemius and soleus muscles but
does not impact hepatic mitochondrial fat oxidation.
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Figure 7. gAcrp30 increases the switch from glucose to fat oxidation in skeletal
muscle in vivo. (A) Hepatic citrate synthase flux rate in control and gAcrp30-treated mice
(n = 10). (B) Hepatic pyruvate carboxylase flux rate (n = 10). (C)-(D) Western blot images
for basal 5' AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase (ACC)
phosphorylation in liver. Quantification is shown below. (E)-(G) Ratio of mitochondrial
ketone oxidation and β-oxidation (VFAO) to citrate synthase flux (VCS) in soleus muscle (n
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= 5-6), liver and quadriceps femoris muscle. (H) Fatty acid oxidation rates of solus muscles
with no treatment (control), control + etomoxir, gAcrp30 treatment, gAcrp30 + etomoxir,
Acrp30 treatment, Acrp30 + etomoxir (n = 2-6). (I) Glucose oxidation rates of soleus
muscles with no treatment (control), gAcrp30 treatment, Acrp30 treatment and insulin
treatment (n = 8-14). (J)-(L) Representative western blot images for non-treated, gAcrp30treated and Acrp30-treated AMPK, ACC and endothelial nitric-oxide synthase
phosphorylation in soleus muscle. Quantification is shown below. Data are shown as
mean ± SEM. *p<0.05, **p<0.01, ***p<0.001 by one-way ANOVA with Tukey multiple
comparisons for (H)-(L). *p<0.05 by unpaired Student’s t-test for other panels.
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Globular adiponectin and full-length adiponectin increase lipoprotein lipase activity
and lipid uptake in epidydimal white adipose tissue
To determine whether adiponectin treatment alters ectopic lipid deposition by
changing triglyceride rich lipoprotein metabolism, we performed a series of studies
assessing very-low-density lipoprotein (VLDL) production and chylomicron clearance. We
first measured the rates of hepatic VLDL-TAG production to evaluate whether hepatic
VLDL-TAG production contributed to the reduced plasma TAG in the gAcrp30-treated
mice. No significant difference in the hepatic VLDL-TAG production rate with gAcrp30
treatment was observed (Fig. 8A and 8B). Then we tested the hypothesis that the
reductions in TAGs and membrane DAGs in liver and skeletal muscle may be explained
by increased uptake of lipids into WAT, thereby diverting circulating triglycerides away
from storage in liver and skeletal muscle. Consistent with the hypothesis, plasma lipid
clearance was increased during an oral lipid tolerance test in the gAcrp30-treated mice
(Fig. 8C and 8D). gAcrp30 treatment promoted increased lipid uptake in epididymal
adipose tissue (eWAT) despite no significant difference in lipid uptake in subcutaneous
WAT (sWAT) or skeletal muscle (Fig. 8E-8G).
Lipoprotein lipase (LPL) plays an important role in the clearance of plasma TAG
and the import of TAG-derived fatty acid to muscle and heart for utilization and adipose
tissues for storage (225). We measured plasma and tissue-specific LPL activity to assess
whether gAcrp30 alters adipose chylomicron clearance via alterations in LPL activity.
gAcrp30 treated mice have increased heparin-releasable LPL activity in plasma and
increased LPL activity in eWAT and heart (Fig. 8H-8J). In contrast, there were no
significant effects of gAcrp30 treatment on sWAT, brown adipose tissue (BAT) or skeletal
muscle LPL activity (Fig. 8K-8M).
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Figure 8. Globular adiponectin increases lipoprotein lipase activity and lipid uptake
in epidydimal white adipose tissue. (A) Plasma triglyceride levels in overnight-fasted
control and gAcrp30 treated mice after an intraperitoneal injection of poloxamer. (B) Liver
triglyceride production rate in control and gAcrp30 treated mice. (C) Plasma triglyceride
concentrations of control and gAcrp30-treated mice during oral lipid tolerance test. (D)
Area under the plasma triglycerides curve of control and gAcrp30-treated mice. (E)-(G)
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Triglyceride uptake in epidydimal white adipose tissue (n = 8-10), subcutaneous white
adipose tissue and skeletal muscle (n = 10) of control and gAcrp30-treated mice. (H) Postheparin plasma LPL activity of control and gAcrp30-treated mice (n = 5). (I) Epidydimal
white adipose tissue LPL activity of control and gAcrp30-treated mice (n = 5). (J) Heart
LPL activity of control and gAcrp30-treated mice. (K) Subcutaneous white adipose LPL
activity of control and gAcrp30-treated mice (n = 5). (L) Brown adipose tissue LPL activity
of control and gAcrp30-treated mice (n = 5-7). (M) Skeletal muscle LPL activity of control
and gAcrp30-treated mice (n = 5). Data are shown as mean ± SEM. *p < 0.05 by unpaired
Student’s t-test.
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It has previously been shown that Acrp30 also reduces plasma and tissue TAG
content in mice liver and skeletal muscle (112, 226). To determine whether the decreased
TAG content by Acrp30 could be explained by similar mechanisms as gAcrp30 treatment,
we performed continuous subcutaneous Acrp30 infusions (10μg/day) in HFD-fed mice for
two weeks and a series of studies assessing chylomicron clearance and LPL activity. As
expected, plasma TAG was decreased with Acrp30 treatment (Fig. 9A). Analogous to
what we observed in gAcrp30 treated mice, two-week Acrp30 treatment increased lipid
clearance during the oral lipid tolerance test and improved lipid uptake in eWAT, without
significant difference in lipid uptake in sWAT or skeletal muscle (Fig. 9A-9E). Acrp30
infusion also increased heparin-releasable plasma LPL activity and increased LPL activity
in eWAT and BAT (Fig. 9F-9H). No significant differences in sWAT, heart and muscle
were observed (Fig. 9I-9K). Taken together, these data demonstrate that both full-length
and globular adiponectin treatment enhances lipid uptake in eWAT, which may be
attributed to localized stimulation of LPL activity in eWAT.
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Figure 9. Globular adiponectin and full-length adiponectin increase lipoprotein
lipase activity and lipid uptake in epidydimal white adipose tissue. (A) Plasma
triglyceride concentrations of control and Acrp30-treated mice during oral lipid tolerance
test. (B) Area under the plasma triglycerides curve of control and Acrp30-treated mice.
(C)-(E) Triglyceride uptake in epidydimal white adipose tissue, subcutaneous white
adipose tissue and skeletal muscle of control and Acrp30-treated mice. (F) Post-heparin
plasma LPL activity of control and Acrp30-treated mice. (G) Epidydimal white adipose
tissue LPL activity of control and Acrp30-treated mice. (H) Brown adipose tissue LPL
activity of control and Acrp30-treated mice. (I) Subcutaneous white adipose LPL activity
of control and Acrp30-treated mice. (J) Heart LPL activity of control and Acrp30-treated
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mice. (K) Skeletal muscle LPL activity of control and Acrp30-treated mice. Data are shown
as mean ± SEM. *p < 0.05, ***p<0.001 by unpaired Student’s t-test.
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DISCUSSION
White adipose tissue is not only a critical energy storage depot, but it also acts as
an endocrine organ sensing metabolic signals and secreting hormones and
adipocytokines (e.g. leptin and adiponectin) that regulate whole-body energy homeostasis
(196, 227-229). Consistent with previous reports (111, 115, 208), we have demonstrated
that administration of globular adiponectin results in an improvement in whole-body
glucose homeostasis. Despite great interest in adiponectin, the mechanism by which
adiponectin reverses insulin resistance had remained unclear. To address this question,
we performed a comprehensive series of studies including hyperinsulinemic-euglycemic
clamp studies combined with stable- and radio-labeled isotopic tracers to characterize
adiponectin’s effects on endogenous glucose production and tissue-specific insulin
sensitivity and followed these studies up by measuring bioactive lipid metabolites and
cellular insulin signaling phosphorylation events in liver, skeletal muscle and WAT.
Adiponectin receptor associated ceramidase activity, promoting decreased total
hepatic ceramide content and ceramide-induced insulin resistance, has been proposed to
mediate adiponectin’s insulin-sensitizing properties (114). However, in contrast to this
hypothesis, we dissociated changes in total ceramide content in the liver and skeletal
muscle from gAcrp30-induced improvements in liver and muscle insulin sensitivity. The
results are different possibly because 1) the mouse models we used are different.
Scherer’s group used ob/ob mice and transgenic mice, but we used HFD-fed WT mice; 2)
the treatment and dose of adiponectin are different. They performed an acute (60-min)
intravenous injection of full-length adiponectin and the dose they used (2 μg/g) is
unphysiological large dose, while we did a relatively long-term (2-week) subcutaneous
administration of both full-length or globular adiponectin, and the doses (Acrp30: 10
μg/day and gAcrp30: 2.5 μg/day) we used are more physiological relevant dose. The
chronic treatment may be more relevant for human therapy. We also did not observe any
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significant differences in the content of specific ceramide species (C16:0 and C18:0) which
have been specifically hypothesized to mediate insulin resistance in rodents (78, 221).
While gAcrp30 treatment did not cause a reduction in total tissue ceramide content or in
changes in C16:0 or C18:0 ceramides, it did result in reductions in several hepatic
ceramide species (C16:0, C20:0, C22:0, C24:0 and C24:1) in the plasma membrane which
correlated with improved insulin sensitivity in liver. Whether these specific plasmamembrane associated ceramide species also contributed to alterations in insulin action
will need to be examined in future studies.
Nevertheless, ceramide-induced insulin resistance is thought to alter downstream
insulin signaling at the level of Akt; however we observed that gAcrp30 improved insulin
action at the level of the insulin receptor, which is not compatible with the putative
mechanisms by which adiponectin is thought to mediate insulin resistance at the level of
AKT2 phosphorylation.
In contrast with ceramide-induced insulin resistance, DAG-PKCe induced insulin
resistance can explain improved insulin signaling at the level of the insulin receptor. By
this mechanism, sn-1,2-DAG accumulation in the plasma membrane of liver and muscle
results in nPKC translocation from the cytoplasm to the plasma membrane, leading to
decreased insulin signaling at the level of the insulin receptor due to PKCe activation and
at the level of IRS-1 and IRS-2 associated PI3-kinase due to PKCq activation (17-19). We
observed that 2 weeks of gAcrp30 treatment reduced plasma membrane sn-1,2-DAG in
liver and membrane associated DAG in muscle, leading to decreased PKCε activity in liver
and both PKCθ and PKCε activity in skeletal muscle. As a result, insulin signaling at the
level of insulin receptor kinase increased in both of these tissues. As such, the effect of
globular adiponectin on tissue-specific insulin action appears to occur through reductions
in liver and muscle plasma membrane DAG content resulting in reduced PKCe activation
in liver and reduction in both PKCe and PKCq activation in skeletal muscle.
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In both in vitro and ex vivo studies, adiponectin has been suggested to reduce
triglyceride content in the liver and muscle by enhancing fatty acid oxidation in an AMPK
dependent manner (23, 115, 117, 118, 230). However, Yamauchi et al. found that globular
adiponectin cannot activate hepatic AMPK signaling pathways (112). No competing
hypothesis has yet been published, and so the underlying physiological mechanisms by
which gAcrp30 reduces hepatic TAG are still debated. Further complicating this question,
most mechanistic studies examining adiponectin’s mechanism of action have been
performed purely in vitro and ex vivo, although in vivo studies are critical to understand
the complex inter-organ crosstalk that regulates metabolic physiology. Reduced ectopic
lipid content in liver and skeletal muscle may be due to several factors including: 1)
decreased NEFA flux to these tissues from reduced WAT lipolysis; 2) increased rates of
tissue mitochondrial fatty acid oxidation; and 3) decreased lipid delivered to tissues from
circulating lipoproteins. We evaluated each of these potential mechanisms for the
gAcrp30-induced reductions in ectopic lipids in HFD-fed mice using a comprehensive
series of in vivo metabolic studies. While gAcrp30 appeared to suppress rates of WAT
lipolysis, as reflected by reduced rates of glycerol turnover and increased WAT insulin
sensitivity, as reflected by increased insulin-stimulated glucose uptake, it did not affect
whole-body fatty acid turnover potentially due to compensatory changes in re-esterification.
Additionally, hepatic mitochondrial fatty acid oxidation and the regulation of fat oxidation
in liver were unchanged. In gastrocnemius and soleus muscle, gAcrp30 treatment
increases muscle fatty oxidation in vivo and ex vivo, an effect that was correlated with
increased phosphorylation of ACC in a manner consistent with previously described
eNOS/AMPK-dependent regulation of ACC (224). This increase in skeletal muscle fatty
acid oxidation could account, in part, for the reduced ectopic lipid deposition seen in
several tissues in gAcrp30 treated mice, and the improvement in muscle insulin sensitivity.
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In addition to promoting increased muscle fatty acid oxidation, we also found that
both gAcrp30 and Acrp30 treatment reduces ectopic lipid (TAG/plasma membrane DAG)
accumulation in liver and skeletal muscle by improving WAT triglyceride uptake and further
increasing WAT storage capacity. Adiponectin-treated mice displayed increased LPL
activity in post-heparin plasma and eWAT, and improved adipose postprandial
triacylglycerol uptake. These results are consistent with our observations that two weeks
of gAcrp30 or Acrp30 treatment increased eWAT mass but did not change total fat mass,
as assessed by 1H NMR.
Our findings also imply an important role for decreased plasma adiponectin in the
development of lipid-induced liver and skeletal muscle insulin resistance. In humans and
monkeys, plasma adiponectin levels correlate significantly with whole-body insulin
sensitivity (25, 26). Overexpression or administration of adiponectin in mice results in a
decrease in hyperglycemia and improvement in systemic insulin sensitivity (23, 27),
whereas adiponectin-deficient mice exhibit impaired insulin sensitivity and are prone to
diabetes (24, 28). Tying all of this together, circulating adiponectin may be a reflection of
the presence of functioning adipose tissue, a part of the machinery the WAT uses in its
fat-storing operation. In normal physiology, healthy adipose tissue secretes sufficient
adiponectin to promote storage of circulating triglyceride in WAT, and signal a shift to
increase fatty acid oxidation in skeletal muscle. However, in obesity, as adipose tissue
has limited storage capacity, WAT secretion of adiponectin decreases. This derangement
in fat storage and muscle fat oxidation may then lead to increased ectopic lipid (TAGs/
plasma membrane DAGs) accumulation in liver and skeletal muscle and the subsequent
development of insulin resistance in these organs leading to the metabolic syndrome,
hepatic steatosis/NASH, and atherosclerosis.
Taken together, these results suggest that chronic adiponectin administration
ameliorates insulin resistance in an HFD-fed mouse model of obesity, NAFLD and insulin
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resistance by two major mechanisms. First, adiponectin treatment promotes increased
WAT LPL activity, which may lead to increased uptake of triglyceride into WAT thus
diverting circulating triglyceride away from storage in liver and skeletal muscle. Second,
adiponectin treatment promotes increased fatty acid oxidation in skeletal muscle, which in
turn may be attributed to the activation of AMPK and eNOS. These two effects of
adiponectin in turn lead to reductions in liver and muscle membrane associated sn-1,2DAG content, resulting in decreased PKCε activity in liver and decreased PKCε and PKCθ
in muscle resulting in increased insulin signaling and insulin action in these tissues.
Furthermore adiponectin-induced improvement in liver and muscle insulin sensitivity in
insulin resistant HFD-fed mice occurred independently of changes in total ceramide
content in these tissues. Taken together, these studies provide new insights into the
mechanisms by which adiponectin reverses HFD-induced liver and muscle insulin
resistance in mice.
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METHODS
Animals and diets
All rodent studies were approved by the Yale University Institutional Animal Care
and Use Committee. Male C57BL/6J mice (Jackson Laboratory) were group housed at
the animal care facility at Yale University Animal Research Center and maintained under
controlled temperature (23°C) and lighting (12:12 h light/dark cycle, lights on at 7:00 AM)
with free access to water and food. Diet-induced obesity studies were carried out by
feeding mice a high fat diet (60% calories from fat, Research Diets D12492). To study the
effects of adiponectin treatment, following 2 weeks or 10 weeks of HFD, mini-osmotic
pumps (Alzet) containing recombinant mouse globular adiponectin protein (Abcam),
recombinant mouse full-length adiponectin (Abcam) or vehicle (saline) were implanted
subcutaneously. Adiponectin was released at a rate of 2.5 μg/day (globular adiponectin)
or 10 μg/day (full-length adiponectin) for 14 days based on previous literature (112, 115).
Food and water intake measurements and indirect calorimetry were performed using
Columbus Lab Animal Monitoring System metabolic cages (Columbus Instruments).
During this time, food intake and body weight were regularly monitored. The mice used
for euglycemic clamp and in vivo tracer studies underwent surgery under isoflurane
anesthesia to place catheters in the jugular vein and single-housed mice were allowed to
recover 6-7 days before planned experiments.

Hyperinsulinemic-euglycemic clamps
Clamps were performed as previously described (9, 18). Briefly, after an overnight
fast, a 120-min basal infusion with [3-3H] glucose (PerkinElmer) at a rate of 0.05 μCi/min,
[1,1,2,3,3-D5] glycerol (Sigma Aldrich) at a rate of 1.5 μmol/(kg-min)and potassium [13C16]
palmitate (Cambridge Isotopes) at a rate of 0.7 μmol/(kg-min) was performed. After the
basal period, mice underwent a 140 min hyperinsulinemic-euglycemic clamp by infusing
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[3-3H] glucose, [1,1,2,3,3-D5] glycerol and potassium [13C16] palmitate at the rates indicated
above, and in the last 55 minutes of the clamp period, 2-deoxy-[1-14C] glucose (2-DG)
(PerkinElmer) was given to estimate tissue-specific glucose uptake. 20% dextrose
(Hospira) at a variable rate and insulin at a rate of 3mU/[kg-min] was infused through the
jugular venous catheter to maintain a steady state plasma glucose concentration of ~120
mg/dL. Plasma glucose concentrations were measured every 10-15 min during the
hyperinsulinemic-euglycemic clamp period. At the end of the study, mice were euthanized
with intravenous pentobarbital and tissues were obtained following the clamp study using
freeze-clamps pre-cooled in liquid nitrogen. The specific activity of glucose was measured
in plasma samples collected at the steady state during basal and clamp by liquid
scintillation counting.

Flux measurement
Positional isotopomer NMR tracer analysis (PINTA) was applied to measure rates
of hepatic mitochondrial citrate synthase flux (VCS) and pyruvate carboxylase flux (VPC) as
previously described(223). Infusion of [3-3H] glucose (PerkinElmer) at a rate of 0.05
μCi/min and [3-13C] sodium lactate (Cambridge Isotopes) at a rate of 40 μmol/(kg-min)
was performed for a total of 120 min to measure VPC/VCS and VPC/VEGP as we previously
described(223).
The ratio of pyruvate dehydrogenase flux to citrate synthase flux (VPDH/VCS) was
used to indicate tissue-specific metabolic substrate oxidation after a 2 hr infusion of
[1,2,3,4,5,6-13C6]glucose (16.7 μmol/[kg-min] prime for 5 min, 5.6 μmol/[kg-min]
continuous infusion) as previously described (231). Briefly, VPDH/VCS was measured as the
ratio of [4,5-13C2]glutamate/[13C3]alanine. [13C3]alanine enrichment was measured by GCMS and [4,5-13C2]glutamate enrichment was measured by liquid chromatography-tandem
mass spectrometry (LC-MS/MS) as previously described (211).
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[1,1,2,3,3-D5]glycerol and [13C16]palmitate enrichments were measured using gas
chromatography-mass spectrometry (GC/MS) as previously described (231). Briefly,
glycerol turnover = ([1,1,2,3,3-D5] glycerol tracer enrichment/[1,1,2,3,3-D5] glycerol
plasma enrichment-1) x infusion rate. Palmitate turnover = ([13C16] palmitate tracer
enrichment/[13C16] palmitate plasma enrichment-1) x infusion rate. Fatty acid turnover =
Palmitate turnover rate/ (palmitate/total fatty acids).

Palmitate and glucose oxidation measurement ex vivo
Ex vivo muscle oxidation measurements were performed as previously described
(232) with minor modifications. Briefly, mice were fasted overnight (12 h) before the
procedure. Animals were euthanized during tissue collection under isoflurane anesthesia;
intact soleus muscles were rapidly removed and pinned in stainless steel clips to maintain
resting tension. Muscles were preincubated in Krebs-Ringer bicarbonate buffer (KRBB),
with 10 mM glucose and 0.5 % BSA, pH 7.4, at 35°C, for 30-45 min. Soleus muscles were
then incubated in the same buffer containing either radiolabeled palmitic acid [0.1 mM
palmitic acid (Sigma Aldrich) and 0.2 μCi/mL [1-14C]palmitic acid (PerkinElmer)] or
radiolabeled glucose [10 mM glucose (Sigma Aldrich) and 0.2 μCi/mL [14C6]D-glucose
(PerkinElmer)] for one hour. 14CO2 produced was trapped in NaOH (0.3 mL at 2 N) during
incubation. Muscles were removed, washed in cold saline for one min, blotted on filter
paper, and weighed. Incubation vials were tightly capped and 0.5 mL of 2 N HCl added
directly to the KRBB using a syringe; vials were incubated for 2 h at 37°C.

14

CO2 absorbed

in NaOH solution was then quantified by scintillation counting.

Biochemical analysis
Plasma glucose was measured enzymatically using a YSI Glucose Analyzer (YSI).
Plasma insulin concentrations were measured by radioimmunoassay (EMD Millipore) at
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the Yale Diabetes Research Center. Plasma NEFA and triglyceride concentrations were
measured by standard spectrophotometric assays (NEFA: Wako Diagnostics;
Triglyceride: Sekisui/Fujifilm). Plasma adiponectin (full-length and globular adiponectin)
concentrations were measured by enzyme-linked immunoassay (ELISA) (Abcam).

Tissue analysis
Liver DAG stereoisomers in five subcellular compartments were measured as
previously described (219, 233). Briefly, liver tissues were first homogenized with a
Doucne-type homogenizer in cold (4°C) TES buffer (250 mM sucrose, 10 mM Tris - pH
7.4, 0.5 mM EDTA). Then the homogenate was centrifuged (at 12,000 rpm with SS-34
rotor or 17,000 g, 15 min, 4°C) to obtain pellet A and supernatant A. The top lipid layer
was collected as the lipid droplet fraction. The supernatant A was washed, centrifuged
and then resuspended in TES buffer and gently layered on top of 1.12 M sucrose buffer
cushion in ultracentrifuge tubes. Then it was centrifuged (at 35,000 rpm with TLS-55 rotor
or 105,000 g, 20 min, 4°C) to obtain pellet B, interface B and supernatant B. The interface
B was collected, washed and centrifuged to get plasma membrane fraction. The pellet B
was washed and centrifuged to obtain mitochondria fraction. The supernatant B was
centrifuged (at 65,000 rpm with Ti-70.1 rotor or 390,000 g, 75 min, 4°C) to separate pellet
C and supernatant C. Pellet C was washed, centrifuged and collected as the endoplasmic
reticulum fraction. Supernatant C was collected as the cytosol fraction. DAG and ceramide
concentrations (19), hepatic long-chain acyl-CoA (19), acetyl- and malonyl-CoA (9) were
measured as previously described.
Tissue TAG content was measured by a standard kit (Sekisui/Fujifilm) after
extraction by the method of Bligh and Dyer (194). For nPKC translocation, cytoplasm and
plasma membrane fractions were separated by ultracentrifugation as previously described
(67, 71).
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Insulin signaling and Western blotting
IRS-1 and IRS-2 associated PI3K activity were determined as previously described
(217). Briefly, IRS-1 and IRS-2 associated PI3K activities were measured in liver and
muscle extracts after immunoprecipitation with IRS-1 antibody (BD Transduction
Laboratories) or IRS-2 antibody (Cell Signaling)/agarose conjugate overnight at 4 °C.
Then the incorporation of

32

P into PI to yield phosphatidylinositol-3-monophosphate was

measured to determine the IRS-1 and IRS-2 associated PI3K activity.
Proteins from tissue lysate were separated by 4–12% sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) (Invitrogen) and then transferred onto
polyvinylidene difluoride membranes (Millipore). After blocking in 5% bovine serum
albumin (BSA)/tris buffered saline with tween (TBST) (10 mM Tris, 100 mM NaCl, and
0.1% Tween-20) solution, membranes were incubated overnight at 4°C with antibodies
obtained from Cell Signaling Technology (pIRK-Y1162, IRK, GAPDH, pAkt-S473, Akt,
pJNK, peNOS, AMPK, pAMPK, ACC, pACC, Perilipin, ATGL, pHSL and HSL), BD
Transduction Laboratories (PKCε, PKCθ and eNOS), Shulman Lab (pIRK T1160)(219),
EMD Millipore (JNK), VALAsciences (pPerilipin)and Abcam (Na/K ATPase and pATGL).
After washing with TBST, membranes were incubated with horseradish peroxidaseconjugated secondary antibodies and detection was performed with enhanced
chemiluminescence. For assaying the IRK-T1160 phosphorylation, after protein
concentration quantitation, protein samples were first immunoprecipitated by Dynabeads
M-270 Epoxy (Invitrogen) conjugated with D2 anti-IR alpha-subunit antibody. The primary
antibody solution was diluted 1:100 – 1:200 for pIRK-T1160 detection.

Hepatic VLDL-TG production
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Hepatic VLDL-TG production was assessed as previously described (234). In
order to determine the basal plasma TAG level, after overnight fasting, blood samples
were collected. Mice were injected intraperitoneally with poloxamer 407 (1g/ kg of body
weight; Sigma Aldrich) to inhibit tissue LPL activity and blood samples were collected at
1, 2, 3, 4 hours after injection. The VLDL-TG production rate was calculated by the
resultant increase in plasma TAG concentrations.

Oral lipid tolerance test and tissue-specific lipid uptake
Lipid clearance and tissue-specific uptake were measured by using [9,10-3H]
triolein as previously described (234, 235). After overnight fasting, mice received a gavage
of a mixed meal: 10ul/g 10% dextrose in Intralipid (20%; Abbott Laboratories) conjugated
with 10μCi of [9,10-3H]triolein (PerkinElmer). Blood was collected by tail vein massage at
0, 1, 2, 3, and 4h for plasma TAG determination. Plasma TAG concentrations was
measured by a standard kit (Sekisui/Fujifilm) and 3H radioactivity was measured by
scintillation counter.

Lipoprotein lipase activity assay
LPL activity was assessed as previously described (236, 237). Briefly, for plasma
LPL activity, blood samples were collected after overnight fasting to determine basal
plasma TAG and LPL activity. Then mice were injected intravenously with heparin (50U/
kg of body weight) and blood samples were taken after 10 minutes injection. Post-heparin
plasma LPL activity was assessed by a fluorometric assay (Cell Biolabs). Tissue LPL was
extracted by incubation of tissue at 37°C for 1 h in phosphate-buffered saline (PBS) with
5 U/ml heparin and 2 mg/ml bovine serum albumin. Samples were centrifuged at 900g for
15 minutes and the supernatant tissue LPL activities were measured in the presence of
heat-inactivated mouse serum using a fluorometric assay (Cell Biolabs).
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Statistical analysis
All data are expressed as the mean ± SEM. Results were assessed using twotailed unpaired Student’s t-test or two-way ANOVA. *P<0.05, **P<0.01, *P<0.05, **P<0.01,
***P<0.001, ****P<0.0001. GraphPad Prism 8.0 was used for all statistical analyses. In
most cases, n = 6-9 per group, unless otherwise indicated in the figure legends.

128

Chapter 7
Summary and Future directions
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Multiple studies have shown that chronic low-grade inflammation in obesity is a
major pathogenic factor associated with insulin resistance and type 2 diabetes in both
rodents and humans. However, the molecular mechanisms by which inflammation
regulates whole-body metabolic dysfunction have remained elusive. O-GlcNAc signaling
has been shown to be involved in neutrophil chemotaxis, B cell activation, and T cell selfrenewal and activation. Recent studies also show that downregulation of O-GlcNAc
signaling promotes innate immune responses in acute microbial infection. Together, these
results suggest that O-GlcNAc signaling plays important roles in fine-tuning immune
responses under various nutritional and pathological conditions. Those findings raised the
question of whether O-GlcNAc signaling in macrophage senses metabolic status and
directly regulates whole-body metabolic homeostasis. To test the hypothesis, we
developed an OGT MKO mouse model and utilized comprehensive methods to elucidate
the mechanisms. For the first time, we demonstrate an anti-inflammatory, anti-diabetic role
of macrophage O-GlcNAc signaling. Our study showed several essential roles that OGlcNAc homeostasis plays in immune actions and metabolic actions in response to
excessive calorie intake, including: 1) reduced O-GlcNAc signaling increases macrophage
pro-inflammatory activation; 2) increases WAT inflammation and lipolysis; 3) increases
fatty acid delivery to liver and skeletal muscle and reduces TAG, DAG content, resulting
in reduced novel PKC activation and impaired insulin sensitivity. Furthermore, we found
that O-GlcNAc signaling regulates mTORC1/S6K1 and AMPK pathways, which are the
novel pathways to regulate macrophage activation. Taken together, this study defines OGlcNAc signaling as a suppressor of pro-inflammatory macrophage activation and adds
new insight into metabolic regulation of macrophage activation. O-GlcNAc signaling may
serve as a novel target to treat obesity-induced insulin resistance, hepatic steatosis and
type 2 diabetes.
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For future work, it would be interesting to figure out why O-GlcNAc signaling is
reduced during LPS-induced M1 polarization (Fig. 1D and S1D) by tracing the glucose
during WT and OGT MKO macrophage polarization. A growing body of evidence
emphasizes the importance of metabolism in functional activation of macrophages (238).
We hypothesize that the decrease of O-GlcNAc signaling in pro-inflammatory macrophage
may be due to increased glucose utilization (e.g., glycolysis and/or glucose oxidation).
Studies have been shown that microglial inflammation determines the immunologic
response of the mediobasal hypothalamus to dietary excess and regulates hypothalamic
control of energy homeostasis in mice (239). We observed that HFD-fed OGT MKO mice
had increased food intake (Fig. S3L), suggesting that microglial inflammation may also
play a role. The mechanisms linking microglia inflammation and its metabolic
consequences could also be studied.
As indicated by these data, suppressing inflammation and ameliorating insulin
resistance could be important to treat type 2 diabetes. Adiponectin has emerged as a
promising therapeutic agent to reduce inflammation and ameliorate insulin resistance. We
then performed a comprehensive set of metabolic flux analyses to assess the effects of
long-term adiponectin treatment on glucose and lipid metabolism in vivo and understand
the underlying mechanisms. I hypothesize that adiponectin administration will result in
reduced ectopic lipid accumulation due to increased mitochondrial oxidation, decreased
lipolysis and/or reduced lipid uptake into liver and skeletal muscle, leading to improved
insulin sensitivity. By testing possible hypotheses, our results showed that adiponectin
administration ameliorates insulin resistance by two major mechanisms: 1) adiponectin
treatment promotes increased WAT LPL activity, which may lead to increased uptake of
triglyceride into WAT thus diverting circulating triglyceride away from storage in liver and
skeletal muscle; 2) adiponectin treatment promotes increased fatty acid oxidation in
skeletal muscle, which may be attributed to the activation of AMPK and eNOS. The pros
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for adiponectin to become a potential agent to treat type 2 diabetes are: 1) The dose for
adiponectin is relatively small; 2) adiponectin has novel mechanisms of increasing insulin
sensitivity by targeting WAT LPL activity, which could be used as a combination with
currently available therapy. The cons for adiponectin to become a potential therapy are:
1) adiponectin is a protein, which requires a relative restricted storage requirement; 2)
adiponectin could increase WAT mass.
In future studies, it will be essential to elucidate the mechanisms by which
adiponectin specifically activates WAT LPL. One hypothesis is that adiponectin may bind
with scaffold proteins and then bind specific LPL regulators in white adipose tissue to
regulate LPL activity. Another hypothesis is that adiponectin may increase WAT LPL
activity by increasing LPL and VLDL receptor mRNA levels. It has also been uncovered
that one dose of adiponectin injection caused a dramatic increase in the glucose infusion
rate (GINF) within 30-40 minutes in euglycemic clamp (114). However, the underlying
mechanisms are still unclear. It is a very rapid process which may not involve
transcriptional and translational regulation. As a result, a novel yet unknown mechanism
may be involved in the acute injection of adiponectin.
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